E1e2 HCV vaccines and methods of use

Immunogenic compositions of HCV E1 and E2 polypeptides from multiple genotypes, combined with adjuvants, address the challenge of inducing effective immune responses against diverse HCV strains, enhancing protection against chronic infection.

JP2024156917AInactive Publication Date: 2024-11-06THE GOVERNORS OF THE UNIV OF ALBERTA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024130501
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2013-10-04
Filing Date
2024-08-07
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for immunization that induces an effective immune response against multiple HCV genotypes, particularly genotypes 1 and 3, to combat chronic hepatitis C infection.

Method used

Development of immunogenic compositions comprising HCV E1 and E2 polypeptides from two or more different genotypes, optionally with adjuvants like MF59, alum, or CpG oligonucleotide, to stimulate an immune response.

Benefits of technology

The compositions effectively induce neutralizing antibodies and cytotoxic T lymphocyte responses against multiple HCV genotypes, providing broad-spectrum protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156917000001_ABST
    Figure 2024156917000001_ABST
Patent Text Reader

Abstract

To provide immunogenic compositions to elicit immune response to HCV.SOLUTION: Disclosed herein is an immunogenic composition comprising: (a) HCV E1 polypeptide, E2 polypeptide or E1E2 polypeptide from a first hepatitis C virus (HCV) genotype; (b) HCV E1 polypeptide, E2 polypeptide or E1E2 polypeptide from a second hepatitis C virus (HCV) genotype; (c) a pharmaceutically acceptable excipient, where at least one E1 polypeptide and at least one E2 polypeptide are included. The disclosure further provides a method for stimulating immune response to HCV in an individual.SELECTED DRAWING: Figure 7
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application Nos. 61 / 823,712, filed May 15, 2013, and 61 / 887,229, filed October 4, 2013, which are incorporated herein by reference in their entireties.

[0002] Incorporation by reference of sequence listings provided as text files The Sequence Listing is provided herein as a text file, "UALB-017WO SeqList_ST25.txt," created on May 9, 2014, and having a size of 339 KB. The entire contents of the text file are incorporated herein by reference. [Background technology]

[0003] Introduction Hepatitis C virus (HCV) is a blood-borne pathogen that is estimated to infect 150-200 million people worldwide. Infection with HCV can be asymptomatic and sometimes can be cured by the patient without medical intervention. However, the majority of patients develop chronic HCV infection, which can lead to hepatitis, scarring, and even liver failure or liver cancer. In the United States alone, more than 3 million people are chronically infected.

[0004] The HCV virion contains a positive-sense, single-stranded RNA genome of approximately 9.5 kb. The genome encodes a single polyprotein of 3,010–3,030 amino acids. Structural proteins include a core protein that forms the viral nucleocapsid and two envelope glycoproteins, E1 and E2.

[0005] There is a need in the art for immunogenic compositions that induce an immune response against HCV in individuals, resulting in the induction of an effective immune response against the many HCV genotypes found worldwide, e.g., genotypes 1 and 3. Summary of the Invention

[0006] overview The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1 / E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1 / E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in practicing methods of inducing an immune response against HCV. The disclosure further provides methods of stimulating an immune response against HCV in an individual.

[0007] In some embodiments, the present disclosure provides immunogenic compositions comprising: (a) a hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a first HCV genotype; (b) an HCV E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a second HCV genotype; and (c) a pharmaceutically acceptable excipient, wherein the composition comprises at least one E1 polypeptide and at least one E2 polypeptide. In some of these embodiments, the first HCV genotype is genotype 1; and the second HCV genotype is genotype 2. In other cases, the first HCV genotype is genotype 1; and the second HCV genotype is genotype 3. The following embodiments (i) through (xiv) are non-limiting examples, in which the immunogenic compositions comprise: (i) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E1 / E2 polypeptide of HCV genotype 3; (ii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E2 polypeptide of HCV genotype 3; (iii) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (iv) E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (v) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E2 polypeptide of HCV genotype 2; (vi) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (vii) the E1 polypeptide of HCV genotype 1; and the E2 polypeptide of HCV genotype 3; (viii) the E1 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) E2 polypeptide of HCV genotype 1; and E1 polypeptide of HCV genotype 3; (x) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xi) E1 polypeptide of HCV genotype 1; and E2 polypeptide of HCV genotype 2; (xii) the E1 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (xiii) an E2 polypeptide of HCV genotype 1; and an E1 polypeptide of HCV genotype 2; or (xiv) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2.

[0008] In any of the above-described embodiments, the composition may further comprise an HCV E1, E2, or E1 / E2 polypeptide of a third HCV genotype.

[0009] In any of the above-described embodiments, the HCV E2 polypeptide from a first HCV genotype may be wild-type and the HCV E2 polypeptide from a second HCV genotype may be wild-type. In any of the above-described embodiments, the HCV E2 polypeptide from a first HCV genotype may be wild-type and the HCV E2 polypeptide from a second HCV genotype may comprise an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site. In any of the above-described embodiments, the HCV E2 polypeptide from a first HCV genotype may comprise an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site and the HCV E2 polypeptide from a second HCV genotype may be wild-type.

[0010] In the immunogenic composition, the pharmaceutically acceptable excipient may include an adjuvant; optionally, the adjuvant is MF59, alum, poly(DL-lactide-co-glycolide), or a CpG oligonucleotide.

[0011] In other embodiments, the present disclosure provides immunogenic compositions comprising: (a) a hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a first HCV genotype; (b) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a second HCV genotype; (c) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a third HCV genotype; and (d) a pharmaceutically acceptable excipient, wherein the composition comprises at least one E1 polypeptide and at least one E2 polypeptide. In some cases, the first HCV genotype is genotype 1, the second HCV genotype is genotype 2, and the third HCV genotype is genotype 3. The following embodiments (i) through (xvii) are non-limiting examples, and the immunogenic compositions comprise: (i) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3; (ii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and the E2 polypeptide of HCV genotype 3; (iii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (iv) E2 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (v) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E2 polypeptide of HCV genotype 3; (vi) E2 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (vii) E2 polypeptides of HCV genotype 1; E2 polypeptides of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3; (viii) E1 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (x) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; (xi) E1 polypeptide of HCV genotype 1; E2 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xii) E2 polypeptide of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xiii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E1 polypeptide of HCV genotype 3; (xiv) E1 polypeptide of HCV genotype 1; E2 polypeptide of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (xv) E2 polypeptide of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (xvi) an E2 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; or (xvii) E1 polypeptides of HCV genotype 1; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2; and E2 polypeptides of HCV genotype 3.

[0012] In any of the above-described embodiments, the HCV E2 polypeptide from the first HCV genotype may be wild-type, the HCV E2 polypeptide from the second HCV genotype may be wild-type, and the HCV E2 polypeptide from the third HCV genotype may be wild-type. In other cases, the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype comprises an asparagine amino acid substitution at the E2N1 and / or E2N6 sites. In other cases, the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype comprises an asparagine amino acid substitution at the E2N1 and / or E2N6 sites, and the HCV E2 polypeptide from the third HCV genotype is wild-type. In other cases, the HCV E2 polypeptide from a first HCV genotype comprises an asparagine amino acid substitution at the E2N1 and / or E2N6 sites, the HCV E2 polypeptide from a second HCV genotype is wild-type, and the HCV E2 polypeptide from a third HCV genotype is wild-type.

[0013] In any of the above-described embodiments, the pharmaceutically acceptable excipient may include an adjuvant. In any of the above-described embodiments, the adjuvant may be MF59, alum, poly(DL-lactide-co-glycolide), or a CpG oligonucleotide.

[0014] The present disclosure provides a method of inducing an immune response in an individual, comprising administering to the individual an effective amount of an immunogenic composition according to any of the embodiments described herein. [The present invention 1001] (a) a hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a first HCV genotype; (b) with an HCV E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a second HCV genotype; (c) a pharmaceutically acceptable excipient; Including, An immunogenic composition comprising at least one E1 polypeptide and at least one E2 polypeptide. [The present invention 1002] 1001. The composition of claim 1001, wherein said first HCV genotype is genotype 1; and said second HCV genotype is genotype 2. [The present invention 1003] 1001. The composition of claim 1001, wherein said first HCV genotype is genotype 1; and said second HCV genotype is genotype 3. [The present invention 1004] (i) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E1 / E2 polypeptide of HCV genotype 3; (ii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E2 polypeptide of HCV genotype 3; (iii) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (iv) E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (v) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E2 polypeptide of HCV genotype 2; (vi) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (vii) the E1 polypeptide of HCV genotype 1; and the E2 polypeptide of HCV genotype 3; (viii) the E1 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) E2 polypeptide of HCV genotype 1; and E1 polypeptide of HCV genotype 3; (x) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xi) E1 polypeptide of HCV genotype 1; and E2 polypeptide of HCV genotype 2; (xii) the E1 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (xiii) an E2 polypeptide of HCV genotype 1; and an E1 polypeptide of HCV genotype 2; or (xiv) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2 1001. The composition of the present invention comprising: [The present invention 1005] The composition of claim 1004, further comprising an HCV E1, E2, or E1 / E2 polypeptide of a third HCV genotype. [The present invention 1006] 1001. The composition of claim 1001, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type and the HCV E2 polypeptide from the second HCV genotype is wild-type. [The present invention 1007] 1001. The composition of claim 1001, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type and the HCV E2 polypeptide from the second HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site. [The present invention 1008] 1001. The composition of claim 1001, wherein the HCV E2 polypeptide from the first HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site, and the HCV E2 polypeptide from the second HCV genotype is wild-type. [The present invention 1009] 1001. The composition of claim 10, wherein said pharmaceutically acceptable excipient comprises an adjuvant. [The present invention 1010] 1001. The composition of claim 10, wherein said adjuvant is MF59, alum, poly(DL-lactide-co-glycolide), or a CpG oligonucleotide. [The present invention 1011] (a) a hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a first HCV genotype; (b) with an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a second HCV genotype; (c) with an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a third HCV genotype; (d) a pharmaceutically acceptable excipient; Including, An immunogenic composition comprising at least one E1 polypeptide and at least one E2 polypeptide. [The present invention 1012] The immunogenic composition of the present invention, wherein the first HCV genotype is genotype 1, the second HCV genotype is genotype 2, and the third HCV genotype is genotype 3. [The present invention 1013] (i) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3; (ii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and the E2 polypeptide of HCV genotype 3; (iii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (iv) E2 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (v) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E2 polypeptide of HCV genotype 3; (vi) E2 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (vii) E2 polypeptides of HCV genotype 1; E2 polypeptides of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3; (viii) E1 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (x) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; (xi) E1 polypeptide of HCV genotype 1; E2 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xii) E2 polypeptide of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xiii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E1 polypeptide of HCV genotype 3; (xiv) E1 polypeptide of HCV genotype 1; E2 polypeptide of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (xv) E2 polypeptide of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (xvi) an E2 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; or (xvii) E1 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E2 polypeptide of HCV genotype 3. The immunogenic composition of the present invention comprising: [The present invention 1014] 1011. The composition of claim 1011, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype is wild-type. [The present invention 1015] 1011. The composition of claim 1011, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site. [The present invention 1016] 1011. The composition of claim 1011, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site, and the HCV E2 polypeptide from the third HCV genotype is wild-type. [The present invention 1017] 1011. The composition of claim 1011, wherein the HCV E2 polypeptide from the first HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype is wild-type. [The present invention 1018] The composition of claim 1011, wherein said pharmaceutically acceptable excipient comprises an adjuvant. [The present invention 1019] 1011. The composition of claim 10, wherein the adjuvant is MF59, alum, poly(DL-lactide-co-glycolide), or a CpG oligonucleotide. [The present invention 1020] 1. A method for inducing an immune response in an individual, comprising: The method, comprising administering to the individual an effective amount of any one of the compositions of present inventions 1001 to 1019. [The present invention 1021] (a) Hepatitis C virus (HCV) E2 polypeptide of HCV genotype 1a; (b) HCV E1 / E2 heterodimeric polypeptide of HCV genotype 3a; (c) a pharmaceutically acceptable excipient; A composition comprising: [The present invention 1022] The composition of claim 1021, wherein all of said polypeptides are wild-type. [The present invention 1023] The composition of claim 1021, wherein the E2 polypeptide is full-length. [The present invention 1024] 1021. The composition of claim 1021, wherein said E2 polypeptide is a soluble E2 polypeptide. [The present invention 1025] (a) a hepatitis C virus (HCV) E2 polypeptide of HCV genotype 3a or an HCV E1 / E2 heterodimer polypeptide; (b) with an HCV E2 polypeptide or HCV E1 / E2 heterodimer polypeptide of HCV genotype 1a; (c) a pharmaceutically acceptable excipient; A composition comprising: [The present invention 1026] The composition of claim 1025, wherein all of said polypeptides are wild-type. [The present invention 1027] The composition of the present invention 1025, wherein the E2 polypeptide is full-length. [The present invention 1028] 1026. The composition of claim 1025, wherein said E2 polypeptide is a soluble E2 polypeptide. [The present invention 1029] 1. A method for inducing an immune response in an individual, comprising: administering to the individual an effective amount of any one of the compositions of the present inventions 1021 to 1028; The method, wherein the composition is administered in an amount effective to induce neutralizing antibodies against at least HCV genotypes 1a and 3a. [The present invention 1030] 1. A method for inducing an immune response in an individual, comprising: administering to the individual an effective amount of any one of the compositions of the present inventions 1021 to 1028; The method, wherein the composition is administered in an amount effective to induce a cytotoxic T lymphocyte response against at least HCV genotypes 1a and 3a. [The present invention 1031] 1. A method for inducing an immune response in an individual, comprising: administering to the individual an effective amount of any one of the compositions of the present inventions 1021 to 1028; The method, wherein the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. [The present invention 1032] (a) a hepatitis C virus (HCV) E2 polypeptide of HCV genotype 2a or an HCV E1 / E2 heterodimer polypeptide; (b) with an HCV E2 polypeptide or HCV E1 / E2 heterodimer polypeptide of HCV genotype 1a; (c) a pharmaceutically acceptable excipient; A composition comprising: [The present invention 1033] The composition of claim 1032, wherein all of said polypeptides are wild-type. [The present invention 1034] The composition of claim 1032, wherein the E2 polypeptide is full-length. [This invention 1035] The composition of claim 1032, wherein said E2 polypeptide is a soluble E2 polypeptide. [The present invention 1036] 1. A method for inducing an immune response in an individual, comprising: Administering an effective amount of any one of the compositions of inventions 1032 to 1035 to the individual; The method, wherein the composition is administered in an amount effective to induce neutralizing antibodies against at least HCV genotypes 1a and 2a. [This invention 1037] 1. A method for inducing an immune response in an individual, comprising: Administering an effective amount of any one of the compositions of inventions 1032 to 1035 to the individual; The method, wherein the composition is administered in an amount effective to induce a cytotoxic T lymphocyte response against at least HCV genotypes 1a and 2a. [The present invention 1038] 1. A method for inducing an immune response in an individual, comprising: Administering an effective amount of any one of the compositions of inventions 1032 to 1035 to the individual; The method, wherein the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 2a. [This invention 1039] (a) Hepatitis C virus (HCV) E2 or HCV E1 / E2 heterodimeric polypeptide of HCV genotype 1a; (b) with an HCV E2 polypeptide or HCV E1 / E2 heterodimer polypeptide of HCV genotype 2a; (c) with the E2 polypeptide of HCV genotype 3a or the HCV E1 / E2 heterodimer polypeptide; (d) a pharmaceutically acceptable excipient; A composition comprising: [The present invention 1040] The composition of claim 1039, wherein all of said polypeptides are wild-type. [The present invention 1041] The composition of claim 1039, wherein at least one of said E2 polypeptides is full length. [The present invention 1042] 1039. The composition of claim 1039, wherein at least one of said E2 polypeptides is a soluble E2 polypeptide. [This invention 1043] Any of the compositions of 1039 to 1042 of the present invention, which comprises E1 / E2 polypeptide of HCV genotype 7a. [This invention 1044] Any of the compositions of 1039 to 1042 of the present invention, which comprises an E2 polypeptide of HCV genotype 7a. [This invention 1045] 1. A method for inducing an immune response in an individual, comprising: Administering an effective amount of any one of the compositions of inventions 1039 to 1044 to the individual; The method, wherein the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. [The present invention 1046] 1. A method for inducing an immune response in an individual, comprising: Administering an effective amount of any one of the compositions of inventions 1039 to 1044 to the individual; The method, wherein the composition is administered in an amount effective to induce a cytotoxic T lymphocyte response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. [This invention 1047] 1. A method for inducing an immune response in an individual, comprising: Administering an effective amount of any one of the compositions of inventions 1039 to 1044 to the individual; The method, wherein the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. [Brief explanation of the drawings]

[0015] [Figure 1A]Example protein sequences of the core-E1-E2 coding regions of HCV genotype 1 viruses, specifically representative of HCV genotypes 1A, 1B, and 1C, are provided. Genbank database sequences for the coding regions core-E1-E2 were aligned using Geneious software v5.6.4. Glycosylation sites N417 (E2N1) and N532 (E2N6) are highlighted (arrows). Amino acid numbering is according to strain NP_671941 (H77). To maintain amino acid numbering, strains AF139594 and BAA03581 have an amino acid insertion between amino acids 478 and 479 (lysine (K) and alanine (A), respectively) that is not shown (dotted line). SEQ ID NOs: 1-27 are listed from top to bottom. [Figure 1B] This is a continuation of Figure 1A. [Figure 1C] This is a continuation of Figure 1B. [Figure 2A] Protein sequences of the core-E1-E2 coding regions of representative HCV genotypes 3A, 3B, and 3K are provided. Genbank database sequences for the coding regions core-E1-E2 were aligned using Geneious software v5.6.4. Glycosylation sites N417 (E2N1) and N532 (E2N6) are highlighted (arrows). SEQ ID NOs: 28-37 are listed from top to bottom. [Figure 2B] This is a continuation of Figure 2A. [Figure 3]The consensus E1E2 protein sequence of the Alberta HCV genotype 1A isolate (LKS1) is provided. The consensus sequence of the E1E2 coding region was obtained from a patient with HCV genotype 1A (LKS1) (Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada). LKS1 E1E2 is shown compared to H77 genotype 1A (core-E1-E2). LKS1 shares 515 / 555 (92.8%) amino acid identity with H77 in the E1E2 coding region. Glycosylation sites N417 (E2N1) and N532 (E2N6) are highlighted (arrows). SEQ ID NOs: 38, 1, and 39 are listed from top to bottom. [Figure 4] Genotype-specific neutralization by sera from goats immunized with either E1E2 from HCV1 (genotype 1a) or E2 from J6 (genotype 2) is shown. [Figure 5] 1 shows the neutralizing activity of sera from goats immunized against genotype 1a chimeric H77c / JFH1 HCV. [Figure 6] 1 shows the neutralizing activity of sera from goats immunized against genotype 2a chimeric J6 / JFH1 HCV. [Figure 7] Figures 7A and 7B show genotype-specific neutralization and cross-neutralization of HCV by sera from goats immunized with HCV antigens. A) Goats 757 and 714 were immunized with recombinant E1E2 derived from genotype 1a HCV1 sequences. B) Goats 766 and 773 were immunized with E2 derived from genotype 2a J6 sequences. Neutralizing activity against chimeric HCVcc of genotypes 1a-6a was measured. Results were normalized using the neutralizing activity of serum from before immunization as a control. [Figure 8A]1 provides the amino acid sequence of the core-E1-E2 coding region of HCV genotype 7a. The amino acid sequence of the coding region core-E1-E2 of genotype 7a (isolate QC69; Genbank: ABN05226.1) is shown according to the numbering scheme of the reference strain NP_671941 (H77). Glycosylation sites N417 (E2N1) and N533 (E2N6) are highlighted (arrows) (SEQ ID NO: 40). [Figure 8B] This is a continuation of Figure 8A. [Figure 9A] This figure provides an alignment of the amino acid sequences of the core-E1-E2 coding regions of representative HCV2A and HCV2B subtypes. Genbank database sequences for the coding regions core-E1-E2 were aligned using Geneious software v5.6.4. The amino acid numbering shown is according to the common HCV strains ABO47639 (JFH1) and HPCJ8G-J8 (J8) of HCV2A and HCV2B, respectively. SEQ ID NOs: 41 to 53 are listed from top to bottom. [Figure 9B] This is a continuation of Figure 9A. [Figure 9C] This is a continuation of Figure 9B. DETAILED DESCRIPTION OF THE INVENTION

[0016] definition As used herein, the term "hepatitis C virus" ("HCV") refers to any one of the many different genotypes and isolates of hepatitis C virus. Thus, "HCV" encompasses any of the many genotypes, subtypes, or quasispecies of HCV, including, for example, genotypes 1, 2, 3, 4, 6, 7, etc., subtypes (e.g., 1a, 1b, 2a, 2b, 3a, 4a, 4c, etc.), and quasispecies. Representative HCV genotypes and isolates include “Chiron” isolates HCV-1, H77, J6, Con1, isolate 1, BK, EC1, EC10, HC-J2, HC-J5;H C-J6, HC-J7, HC-J8, HC-JT, HCT18, HCT27, HCV-476, HCV-KF, "Hunan", "Japan", "Taiwan", TH, type 1, type 1a, H77 Types 1b, 1c, 1d, 1e, 1f, 10, 2, 2a, 2b, 2c, 2d, 2f, 3, 3a, 3b, 3g, 4, 4a, 4c, 4d, 4f, 4h, 4k, 5, 5a, 6, and 6a.

[0017] The terms "individual," "host," "subject," and "patient" are used interchangeably herein and refer to mammals, including, but not limited to, non-human primates (e.g., monkeys), and humans.

[0018] As used herein, the term "isolated," when referring to a polypeptide, refers to a polypeptide in an environment other than the environment in which the polypeptide naturally occurs. An isolated polypeptide can be purified. "Purified" means that the subject compound (e.g., a polypeptide) has been separated from components that naturally accompany it. "Purified" can also be used to refer to a polypeptide that has been separated from components that may accompany it during the polypeptide's production (e.g., during in vitro synthesis). In some embodiments, a polypeptide (or mixture of polypeptides) is substantially pure when the polypeptide (or mixture of polypeptides) is at least 60% or at least 75% by weight free from organic molecules with which it is naturally associated or with which it is associated during production. In some embodiments, the polypeptide is 30% to 60% pure. In some embodiments, the polypeptide (or mixture of polypeptides) is at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% pure by weight. For example, in some embodiments, an E1 or E2 polypeptide (or a mixture of E1 and E2 polypeptides) is substantially pure if it is at least 60% or at least 75% by weight free from organic molecules to which the polypeptide(s) are naturally associated or to which they are associated during production. In some embodiments, the E1 or E2 polypeptide (or a mixture of E1 and E2 polypeptides) is at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% pure by weight. In some embodiments, when a composition comprises an E2 polypeptide, the E2 polypeptide is at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% pure by weight.In some embodiments, when a composition comprises an E1 / E2 heterodimer complex polypeptide, the E1 / E2 heterodimer complex polypeptide is at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% pure by weight. In some embodiments, when a composition comprises an E2 polypeptide and an E1 / E2 heterodimer complex polypeptide, the E2 polypeptide and the E1 / E2 heterodimer complex polypeptide are at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% pure by weight.

[0019] Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0020] Where a range of values ​​is provided, it is understood that each intervening value between the upper and lower limit of that range (to one-tenth of the place of the lower limit, unless the context clearly indicates otherwise), and any other value or intervening value within that stated range, is encompassed within the invention. The upper and lower limits of these narrower ranges may independently be included in the narrower ranges and are also encompassed within the invention, subject to any particular excluded limit in the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.

[0022] It should be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "an HCV E1 polypeptide" includes a plurality of such polypeptides; a reference to "the HCV genotype" includes a reference to one or more genotypes and equivalents thereof known to those of skill in the art; and so forth. It should further be noted that the appended claims may be drafted to exclude any optional element. Accordingly, this statement is intended to serve as a basis for using exclusive terminology such as "solely," "only," and the like in connection with the enumerated claim elements, or for using "negative" limitations.

[0023] It should be understood that certain features of the invention, which are described for clarity in the context of separate embodiments, may also be provided in combination with the individual embodiments. Conversely, various features of the invention, which are described for brevity in the context of separate embodiments, may also be provided separately or in any suitable subcombination. All combinations of the embodiments related to the invention are specifically embraced by the invention and are disclosed herein just as if each and every combination were individually and expressly disclosed. In addition, all subcombinations of the various embodiments and elements thereof are also specifically embraced by the invention and are disclosed herein just as if each and every such subcombination were individually and expressly disclosed herein.

[0024] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[0025] Detailed Description The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1 / E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1 / E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in practicing methods of inducing an immune response against HCV. The disclosure further provides methods of stimulating an immune response against HCV in an individual.

[0026] immunogenic composition The present disclosure provides immunogenic compositions comprising HCV structural polypeptides, e.g., E1, E2, and / or E1 / E2, where the compositions comprise HCV structural polypeptides from at least two different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1 / E2 polypeptides from two or more different HCV genotypes.

[0027] The immunogenic compositions comprise HCV polypeptides E1, E2, and / or E1 / E2. The E1 and E2 polypeptides present in the immunogenic compositions may be present in the composition as covalently or non-covalently linked heterodimers. The E1 and E2 polypeptides may be present in the composition as a single polypeptide chain, or as two distinct polypeptide chains (which may or may not be covalently linked via disulfide bonds).

[0028] The E1 and E2 polypeptides can be isolated and purified. Optionally, the immunogenic composition comprises E1 and E2 polypeptides, wherein the polypeptides (or a mixture of E1 and E2 polypeptides) are 30% to 60% pure or 60% to about 80% pure. Optionally, the immunogenic composition comprises E1 and E2 polypeptides, wherein the polypeptides (or a mixture of E1 and E2 polypeptides) are at least about 80% pure, at least about 85% pure, at least about 90% pure, at least about 95% pure, at least about 98% pure, at least about 99% pure, or greater than 99% pure. In some embodiments, the immunogenic composition does not contain any other polypeptides (e.g., no other HCV polypeptides) other than the HCV E1 and HCV E2 polypeptides.

[0029] The terms "E1 polypeptide" and "E2 polypeptide" encompass proteins that contain additional modifications to the native sequence, such as deletions (e.g., C-terminal truncations, e.g., a C-terminally truncated E2 lacking the naturally occurring C-terminus described herein), additions, and substitutions (e.g., conservative amino acid substitutions). These modifications may be deliberate, such as through site-directed mutagenesis, or may arise as a result of mutational events during spontaneous or recombinant expression of E1 or E2 (e.g., during HCV infection in vivo, during HCV virus production in cell culture, during recombinant expression, or E1 or E2 in in vitro cell culture).

[0030] E1 HCV E1 polypeptides suitable for use in the immunogenic compositions of the present disclosure may have a length of from about 150 amino acids (aa) to about 175 aa, from about 175 aa to about 195 aa, from about 131 aa to about 175 aa, or from about 175 aa to about 193 aa.

[0031] In Figures 1A-1C, the amino acid sequence of E1 is from amino acid 192 to amino acid 383. In Figures 2A and 2B, the amino acid sequence of E1 is from amino acid 192 to amino acid 384. In Figure 3, the amino acid sequence of E1 is from amino acid 192 to amino acid 385. The amino acid sequence from about amino acid 170 to about amino acid 191 serves as the E1 signal sequence. As used herein, "E1 polypeptide" includes precursor E1 proteins containing a signal sequence; mature E1 polypeptides lacking this sequence; and E1 polypeptides having heterologous signal sequences. E1 polypeptides may include a C-terminal membrane anchor sequence occurring at about amino acid positions 360-383 (see, e.g., WO 96 / 04301). In some cases, suitable E1 polypeptides lack a C-terminal portion containing the transmembrane domain. For example, in some cases, suitable E1 polypeptides lack a C-terminal portion from amino acid 330 to amino acid 384 or from amino acid 360 to amino acid 384. The E1 polypeptide may be an E1 polypeptide of any genotype, subtype, or isolate of HCV. E1 polypeptides of genotype 1 and E1 polypeptides of genotype 3 are of particular interest.

[0032] The E1 polypeptide may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of the E1 polypeptide shown in Figures 1A-1C, 2A and 2B, or 3.

[0033] The E1 polypeptide may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the consensus E1 polypeptide amino acid sequence shown in Figure 3.

[0034] The E1 polypeptide may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of the E1 polypeptide shown in Figures 8A and 8B. For example, the E1 polypeptide of genotype 7A may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to amino acids 192 to 383 of the amino acid sequence shown in Figures 8A and 8B.

[0035] An E1 polypeptide can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of the E1 polypeptide shown in Figures 9A-9C. For example, an E1 polypeptide of genotype 2A can comprise an amino acid sequence identified as 2A and having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to amino acids 192-383 of the amino acid sequence shown in Figures 9A-9C. For example, an E1 polypeptide of genotype 2B can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to amino acids 384 to 751 of the amino acid sequence identified as 2B and shown in Figures 9A-9C.

[0036] E2 E2 polypeptides suitable for use in the present immunogenic compositions may have a length of from about 200 amino acids (aa) to about 250 aa, from about 250 aa to about 275 aa, from about 275 aa to about 300 aa, from about 300 aa to about 325 aa, from about 325 aa to about 350 aa, or from about 350 aa to about 365 aa.

[0037] In Figures 1A-1C, the amino acid sequence of E2 is from amino acid 384 to amino acid 746. In Figures 2A and 2B, the amino acid sequence of E2 is from amino acid 385 to amino acid 754. In Figure 3, the amino acid sequence of E2 is from amino acid 386 to amino acid 746. As used herein, "E2 polypeptide" includes the precursor E2 protein, which includes the signal sequence; the mature E2 polypeptide, which lacks this sequence; and the E2 polypeptide with a heterologous signal sequence. The E2 polypeptide may include a C-terminal membrane anchor sequence, which occurs at approximately amino acid positions 715-730 and may extend to approximately amino acid residue 746 (see Lin et al., J. Virol. (1994) 68:5063-5073).

[0038] In some cases, an E2 polypeptide suitable for use in the immunogenic compositions of the present disclosure lacks a portion of its C-terminal region, e.g., from about amino acid 715 to the C-terminus; from about amino acid 625 to the C-terminus; from about amino acid 661 to the C-terminus; from about amino acid 655 to the C-terminus; or from about amino acid 500 to the C-terminus, where the amino acid numbering refers to the numbering in Figures 1A-1C. See, e.g., U.S. Patent No. 6,521,423.

[0039] An E2 polypeptide suitable for use in the immunogenic compositions of the present disclosure may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of the E2 polypeptide shown in Figures 1A-1C, 2A and 2B, or 3.

[0040] An E2 polypeptide suitable for use in the immunogenic compositions of the present disclosure may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of the E2 polypeptide shown in Figures 8A and 8B. For example, an E2 polypeptide of genotype 7A may comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to amino acids 384 to 750 of the amino acid sequence shown in Figures 8A and 8B.

[0041] An E2 polypeptide suitable for use in the immunogenic compositions of the present disclosure can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of the E2 polypeptide shown in Figures 9A-9C. For example, an E2 polypeptide of genotype 2A can comprise an amino acid sequence identified as 2A and having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to amino acids 384 to 751 of the amino acid sequence shown in Figures 9A-9C. For example, an E2 polypeptide of genotype 2B can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to amino acids 384 to 751 of the amino acid sequence identified as 2B and shown in Figures 9A-9C.

[0042] Modified E2 Polypeptide In some cases, the E2 polypeptide present in the immunogenic composition is modified to reduce glycosylation of the E2 polypeptide compared to wild-type E2 polypeptide. Wild-type HCV E2 is glycosylated at E2N1 and / or E2N6, and the reference strain H77 contains residues Asn-417 and / or Asn-532, respectively. "E2N1" and "E2N6" refer to amino acid sequence motifs that allow N-linked glycosylation of naturally occurring HCV E2 polypeptides, which motifs are located in the E2 polypeptide as shown in the sequences of Figures 1A-1C, 2A-2E, and 5. For example, as shown in Figures 1A-1C, in the reference strain H77 of genotype 1, the E2N1 site contains Asn-417 and the E2N6 site contains Asn-532. As another example, as shown in Figures 2A and 2B, the E2N1 site contains Asn-418 and the E2N6 site contains Asn-534. As another example, as shown in Figures 8A and 8B, the E2N1 site includes Asn-417 and the E2N6 site includes Asn-533.

[0043] Modified E2 polypeptides suitable for inclusion in the immunogenic compositions have a substitution of asparagine at E2N1 and / or E2N6 (e.g., by modification (e.g., substitution) of Asn-417 and / or Asn-532) such that N-linked glycosylation does not occur at these positions. The E2 polypeptide used to produce the modified E2 polypeptide can be an E2 polypeptide of any genotype, subtype, or isolate of HCV. Genotype 1 E2 polypeptides and genotype 3 E2 polypeptides are of particular interest.

[0044] The modified E2 polypeptide can include a modification, e.g., a substitution, of an asparagine at sites E2N1 and / or E2N6 (e.g., Asn-417 and / or Asn-532) such that N-linked glycosylation does not occur at the E2N1 and / or E2N6 positions. The asparagine at E2N1 and / or E2N6 (e.g., Asn-417 and / or Asn-532) can be substituted with any amino acid that is not glycosylated (including N-glycosylated and O-glycosylated). Examples of substitutions include, but are not limited to, N417T (replacement of Asn-417 with threonine), N417S (replacement of Asn-417 with serine), N417Q (replacement of Asn-417 with glutamine), N417Y (replacement of Asn-417 with tyrosine), N417C (replacement of Asn-417 with cysteine), N532T, N532S, N532Q, N532Y, N532C, etc. The location of the substituted asparagine(s) is based on the numbering shown in Figures 1A-1C (HCV genotype 1). The location of the substituted asparagine(s) in genotype 3 is indicated by an arrow in Figures 2A and 2B and Figure 3. The location of the substituted asparagine(s) is also shown in Figure 5.

[0045] The modified E2 polypeptide may have a length of about 200 amino acids (aa) to about 250 aa, about 250 aa to about 275 aa, about 275 aa to about 300 aa, about 300 aa to about 325 aa, about 325 aa to about 350 aa, or about 350 aa to about 365 aa.

[0046] In Figures 1A-1C, the amino acid sequence of E2 is from amino acid 384 to amino acid 746. In Figures 2A and 2B, the amino acid sequence of E2 is from amino acid 385 to amino acid 754. In Figure 3, the amino acid sequence of E2 is from amino acid 386 to amino acid 746. As used herein, "E2 polypeptide" includes the precursor E2 protein, which includes the signal sequence; the mature E2 polypeptide, which lacks this sequence; and the E2 polypeptide with a heterologous signal sequence. The E2 polypeptide may include a C-terminal membrane anchor sequence, which occurs at approximately amino acid positions 715-730 and may extend to approximately amino acid residue 746 (see Lin et al., J. Virol. (1994) 68:5063-5073).

[0047] In some cases, the modified E2 polypeptide lacks a portion of its C-terminal region, e.g., from about amino acid 715 to the C-terminus; from about amino acid 625 to the C-terminus; from about amino acid 650 to the C-terminus; from about amino acid 661 to the C-terminus; from about amino acid 655 to the C-terminus; or from about amino acid 500 to the C-terminus, where the amino acid numbering refers to the numbering in Figures 1A-1C. See, e.g., U.S. Patent No. 6,521,423.

[0048] The modified E2 polypeptide can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of an E2 polypeptide shown in Figures 1A-1C, 2A and 2B, or 3, wherein the modified E2 polypeptide has an asparagine amino acid substitution at E2N1 and / or E2N6 (e.g., Asn-417 and / or Asn-532).

[0049] The modified E2 polypeptide can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of an E2 polypeptide shown in Figures 1A-1C, 2A-2F, or 3, wherein the modified E2 polypeptide has an amino acid substitution of an asparagine at E2N2 (e.g., Asn-417) and the amino acid sequence includes an asparagine at E2N6 (e.g., Asn-532).

[0050] The modified E2 polypeptide can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of an E2 polypeptide shown in Figures 1A-1C, 2A-2F, or 3, wherein the modified E2 polypeptide has an amino acid substitution of an asparagine at E2N6 (e.g., Asn-532) and the amino acid sequence includes an asparagine at E2N1 (e.g., Asn-417).

[0051] The modified E2 polypeptide can comprise an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity to the amino acid sequence of an E2 polypeptide shown in Figures 1A-1C, 2A-2F, or 3, wherein the modified E2 polypeptide has an amino acid substitution of asparagine at E2N1 (e.g., Asn-417) and an amino acid substitution of asparagine at E2N6 (e.g., Asn-532).

[0052] In some cases, in addition to the modifications described above, the modified E2 polypeptide includes an asparagine amino acid substitution at one or more of: 1) the E2N2 site (e.g., residue 423); 2) the E2N4 site (e.g., residue 448); or 3) the E2N11 site (e.g., residue 645).

[0053] Compositions containing HCV E1 of HCV genotype 1 The present disclosure provides immunogenic compositions comprising E1 / E2 of HCV genotype 1. In some cases, the immunogenic composition includes only E1 / E2 of HCV genotype 1, e.g., the immunogenic composition does not include E1 polypeptides, E2 polypeptides, or E1 / E2 heterodimers of any other HCV genotypes.

[0054] Compositions Comprising E1, E2, and / or E1 / E2 of Two Different HCV Genotypes The compositions of the present disclosure comprise (a) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 heterodimeric polypeptide complex from a first HCV genotype; (b) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 heterodimeric polypeptide complex from a second HCV genotype; and (c) a pharmaceutically acceptable excipient, wherein the composition comprises at least one E1 polypeptide and at least one E2 polypeptide. The E2 polypeptide may be present in the composition in a heterodimeric complex with the E1 polypeptide or may be present in the composition uncomplexed with the E1 polypeptide.

[0055] In the compositions described below, "E2" refers to an E2 polypeptide that is not complexed with an E1 polypeptide, while "E1 / E2" refers to E1 and E2 that are present together in a heterodimeric polypeptide complex. Similarly, an E1 polypeptide may be present in a composition in a heterodimeric complex with an E2 polypeptide, or may be present in a composition uncomplexed with an E2 polypeptide. In the compositions described below, "E1" refers to an E1 polypeptide that is not complexed with an E2 polypeptide, while "E1 / E2" refers to E1 and E2 that are present together in a heterodimeric polypeptide complex.

[0056] The compositions of the present disclosure may include: (a) an E1 / E2 heterodimeric polypeptide complex of a first HCV genotype; and an E1 / E2 heterodimeric polypeptide complex of a second HCV genotype; (b) an E1 / E2 heterodimeric polypeptide complex of a first HCV genotype; and an E2 polypeptide of a second HCV genotype; (c) an E2 polypeptide of a first HCV genotype; and an E1 / E2 heterodimeric polypeptide complex of a second HCV genotype; (d) an E1 polypeptide of a first HCV genotype; and an E2 polypeptide of a second HCV genotype; (e) an E1 polypeptide of a first HCV genotype; and an E1 / E2 heterodimeric polypeptide complex of a second HCV genotype; (f) an E2 polypeptide of a first HCV genotype; and an E1 polypeptide of a second HCV genotype; or (g) an E2 polypeptide of a first HCV genotype; and an E1 / E2 heterodimeric polypeptide complex of a second HCV genotype.

[0057] Exemplary compositions of the present disclosure include the following: (1) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (2) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and an E2 polypeptide of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (3) E2 polypeptides of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (4) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2, e.g., wherein all polypeptides are wild-type; (5) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and an E2 polypeptide of HCV genotype 2, e.g., wherein all polypeptides are wild-type; (6) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2, e.g., wherein all polypeptides are wild-type; (7) An E1 polypeptide of HCV genotype 1; and an E2 polypeptide of HCV genotype 3, for example, wherein all polypeptides are wild-type; (8) E1 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3, for example, wherein all polypeptides are wild-type; (9) E2 polypeptide of HCV genotype 1; and E1 polypeptide of HCV genotype 3, for example, wherein all polypeptides are wild-type; (10) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3, for example, wherein all polypeptides are wild-type; (11) An E1 polypeptide of HCV genotype 1; and an E2 polypeptide of HCV genotype 2, for example, wherein all polypeptides are wild-type; (12) E1 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2, e.g., wherein all polypeptides are wild-type; (13) E2 polypeptide of HCV genotype 1; and E1 polypeptide of HCV genotype 2, for example, wherein all polypeptides are wild-type; (14) E2 polypeptides of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2, for example, in which all polypeptides are wild-type.

[0058] In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the combination of genotypes 1 and 2 or the combination of genotypes 1 and 3 described above.

[0059] As discussed above, the E2 polypeptide can have a wild-type HCV E2 amino acid sequence, e.g., where the E2 polypeptide does not have an asparagine amino acid substitution at the E2N1 and / or E2N6 sites. A "wild-type" HCV E2 polypeptide comprises the amino acid sequence of an HCV E2 polypeptide found in nature.

[0060] As noted above, in some embodiments, the E2 polypeptide may include an asparagine amino acid substitution at the E2N1 and / or E2N6 sites. The following are exemplary compositions: 15) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3, wherein the E2 polypeptide is wild-type; 16) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1, wherein the E2 polypeptide is wild-type; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; 17) An E1 / E2 heterodimeric polypeptide complex of HCV genotype 1, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; and an E2 polypeptide of HCV genotype 3, wherein the E2 polypeptide is wild-type; 18) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1, wherein the E2 polypeptide is wild-type; and E2 polypeptides of HCV genotype 3, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; 19) E2 polypeptides of HCV genotype 1, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3, wherein the E2 polypeptide is wild-type; 20) E2 polypeptides of HCV genotype 1, wherein the E2 polypeptide is wild-type; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; 21) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2, wherein the E2 polypeptide is wild-type; 22) E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1, wherein the E2 polypeptide is wild-type; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; 23) An E1 / E2 heterodimeric polypeptide complex of HCV genotype 1, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; and an E2 polypeptide of HCV genotype 2, wherein the E2 polypeptide is wild-type; 24) An E1 / E2 heterodimeric polypeptide complex of HCV genotype 1, wherein the E2 polypeptide is wild-type; and an E2 polypeptide of HCV genotype 2, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; 25) E2 polypeptides of HCV genotype 1, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2, wherein the E2 polypeptide is wild-type; 26) E2 polypeptides of HCV genotype 1, wherein the E2 polypeptide is wild-type; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above.

[0061] Compositions containing E2 or E1 / E2 of two different HCV genotypes The compositions of the present disclosure comprise (a) an HCV E2 polypeptide or an E1 / E2 heterodimeric polypeptide complex from a first HCV genotype; (b) an HCV E2 polypeptide or an E1 / E2 heterodimeric polypeptide complex from a second HCV genotype; and (c) a pharmaceutically acceptable excipient. The E2 polypeptide may be present in the composition in a heterodimeric complex with an E1 polypeptide, or may be present in the composition uncomplexed with an E1 polypeptide. The E2 polypeptide may be soluble.

[0062] The compositions of the present disclosure may comprise one of (a)-(k) as described below, wherein the composition comprises a pharmaceutically acceptable excipient.

[0063] (a) an E2 polypeptide of HCV genotype 1a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not comprise an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of at least one additional HCV genotype.

[0064] (b) a full-length E2 polypeptide of HCV genotype 1a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not comprise an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of at least one additional HCV genotype.

[0065] (c) a soluble E2 polypeptide of HCV genotype 1a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not comprise an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of at least one additional HCV genotype.

[0066] (d) an E2 polypeptide of HCV genotype 1a, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 and / or E2N6 sites as described above; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein the E2 polypeptide of the E1 / E2 heterodimer is wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0067] (e) an E2 polypeptide of HCV genotype 1a, wherein the E2 polypeptide is wild-type; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0068] (f) an E2 polypeptide of HCV genotype 3a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not comprise an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of at least one additional HCV genotype.

[0069] (g) a full-length E2 polypeptide of HCV genotype 3a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not comprise an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of at least one additional HCV genotype.

[0070] (h) a soluble E2 polypeptide of HCV genotype 3a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not comprise an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of at least one additional HCV genotype.

[0071] (i) an E2 polypeptide of HCV genotype 3a, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 and / or E2N6 sites as described above; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein the E2 polypeptide of the E1 / E2 heterodimer is wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0072] (j) E2 polypeptides of HCV genotype 3a, wherein the E2 polypeptide is wild-type; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 1a, wherein the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 and / or E2N6 sites as described above. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0073] (k) an E2 polypeptide or an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; and an E2 polypeptide or an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2a. Optionally, all of the polypeptides are wild-type. Optionally, the genotype 1a and genotype 2a polypeptides are both E1 / E2 heterodimeric polypeptides. Optionally, the genotype 1a polypeptide is an E2 polypeptide; and the genotype 2a polypeptide is an E1 / E2 heterodimeric polypeptide complex. Optionally, the genotype 1a polypeptide is an E1 / E2 heterodimeric polypeptide complex; and the genotype 2a polypeptide is an E2 polypeptide. Optionally, the genotype 1a and genotype 2a polypeptides are both E2 polypeptides. Optionally, the genotype 1a and genotype 2a polypeptides are both soluble E2 polypeptides. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes, such as genotypes 1a, 1b, 2a, 4, 5, and 6a. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a, 1b, 2a, 4, 5, and 6a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 2a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0074] In any of the above-described embodiments, E2 from HCV genotype 1a (either unconjugated E2 or an E1 / E2 heterodimer complex) may be replaced with E2 from HCV genotype 1, 4, 5, or 6 (either unconjugated E2 or an E1 / E2 heterodimer complex).

[0075] Compositions containing E1, E2, and / or E1 / E2 of three different HCV genotypes The compositions of the present disclosure comprise (a) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 heterodimeric polypeptide complex from a first HCV genotype; (b) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 heterodimeric polypeptide complex from a second HCV genotype; (c) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 heterodimeric polypeptide complex from a third HCV genotype; and (d) a pharmaceutically acceptable excipient, wherein the composition comprises at least one E1 polypeptide and at least one E2 polypeptide. The E2 polypeptide may be present in the composition in a heterodimeric complex with the E1 polypeptide or may be present in the composition uncomplexed with the E1 polypeptide. In the compositions described below, "E2" refers to the E2 polypeptide not complexed with the E1 polypeptide, while "E1 / E2" refers to E1 and E2 present together in a heterodimeric polypeptide complex. Similarly, the E1 polypeptide may be present in the composition in a heterodimeric complex with an E2 polypeptide, or may be present in the composition uncomplexed with an E2 polypeptide. In the compositions described below, "E1" refers to the E1 polypeptide uncomplexed with an E2 polypeptide, while "E1 / E2" refers to E1 and E2 present together in a heterodimeric polypeptide complex.

[0076] The compositions of the present disclosure may include: (i) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (ii) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E2 polypeptide of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (iii) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (iv) an E2 polypeptide of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (v) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E2 polypeptide of HCV genotype 3, e.g., wherein all polypeptides are wild-type; (vi) E2 polypeptides of HCV genotype 1; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2; and E2 polypeptides of HCV genotype 3, e.g., where all polypeptides are wild-type; (vii) an E2 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3, e.g., wherein all polypeptides are wild-type. (viii) E1 polypeptide of HCV genotype 1; E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (x) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; (xi) E1 polypeptide of HCV genotype 1; E2 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xii) E2 polypeptide of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xiii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E1 polypeptide of HCV genotype 3; (xiv) E1 polypeptide of HCV genotype 1; E2 polypeptide of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (xv) E2 polypeptide of HCV genotype 1; E1 polypeptide of HCV genotype 2; and E2 polypeptide of HCV genotype 3; (xvi) an E2 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; (xvii) E1 polypeptides of HCV genotype 1; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2; and E2 polypeptides of HCV genotype 3.

[0077] In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1, 2, and 3. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 7.

[0078] In any of the above-described compositions, the E2 polypeptide can have a wild-type HCV E2 amino acid sequence, e.g., where the E2 polypeptide does not have an asparagine amino acid substitution at the E2N1 and / or E2N6 sites. A "wild-type" HCV E2 polypeptide comprises the amino acid sequence of an HCV E2 polypeptide found in nature. In some embodiments, the E2 polypeptide can include an asparagine amino acid substitution at the E2N1 and / or E2N6 sites.

[0079] Compositions containing E2 and / or E1 / E2 of three different HCV genotypes The compositions of the present disclosure comprise (a) an HCV E2 polypeptide or E1 / E2 heterodimer polypeptide complex from a first HCV genotype; (b) an HCV E2 polypeptide or E1 / E2 heterodimer polypeptide complex from a second HCV genotype; (c) an HCV E2 polypeptide or E1 / E2 heterodimer polypeptide complex from a third HCV genotype; and (d) a pharmaceutically acceptable excipient. The E2 polypeptide may be present in the composition in a heterodimer complex with an E1 polypeptide, or may be present in the composition uncomplexed with an E1 polypeptide. The E2 polypeptide may be soluble.

[0080] The compositions of the present disclosure may comprise one of (a)-(f) as described below, wherein the composition comprises a pharmaceutically acceptable excipient.

[0081] (a) an E2 polypeptide of HCV genotype 1a; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2a; and an E2 polypeptide of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0082] (b) E2 polypeptides of HCV genotype 1a; E2 polypeptides of HCV genotype 2a; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptides of the E1 / E2 heterodimer include asparagine modifications (e.g., substitutions) at the E2N1 and / or E2N6 sites as described above. In other cases, the E2 polypeptides not present in heterodimeric complexes with E1 include asparagine modifications (e.g., substitutions) at the E2N1 and / or E2N6 sites as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0083] (c) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; an E2 polypeptide of HCV genotype 2a; and an E2 polypeptide of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0084] (d) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2a; and an E2 polypeptide of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0085] (e) E2 polypeptides of HCV genotype 1a; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2a; and E1 / E2 heterodimeric polypeptide complexes of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptides of the E1 / E2 heterodimer include asparagine modifications (e.g., substitutions) at the E2N1 and / or E2N6 sites as described above. In other cases, the E2 polypeptides not present in heterodimeric complexes with E1 include asparagine modifications (e.g., substitutions) at the E2N1 and / or E2N6 sites as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0086] (f) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; an E2 polypeptide of HCV genotype 2a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0087] Methods for producing E1 and E2 polypeptides The E1 and E2 polypeptides can be produced by any suitable method, including recombinant and non-recombinant methods (eg, chemical synthesis).

[0088] When a polypeptide is chemically synthesized, synthesis can proceed via liquid phase or solid phase. Solid phase peptide synthesis (SPPS) allows the incorporation of unnatural amino acids and / or modification of the peptide / protein backbone. Various types of SPPS, such as Fmoc and Boc, are available for synthesizing polypeptides. Details of chemical synthesis are known in the art (e.g., Ganesan A. 2006 Mini Rev. Med Chem. 6:3-10, and Camarero JA et al., 2005 Protein Pept Lett. 12:723-8).

[0089] When a polypeptide is produced using recombinant techniques, the polypeptide can be produced as an intracellular or secreted protein using any suitable construct and any suitable host cell, which can be a prokaryotic or eukaryotic cell, such as a bacterial cell (e.g., Escherichia coli) or a yeast host cell, respectively. Other examples of eukaryotic cells that can be used as host cells include insect cells, mammalian cells, filamentous fungi, and plant cells. Suitable yeast cells include, for example, Saccharomyces cerevisiae and Pichia (e.g., Pichia pastoris).

[0090] Suitable mammalian cell lines include human cell lines, non-human primate cell lines, rodent (eg, mouse, murine) cell lines, and the like. Suitable mammalian cell lines include, but are not limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-2), CHO cells (e.g., ATCC Nos. CRL9618, CCL61, CRL9096), 293 cells (e.g., ATCC No. CRL-1573), Vero cells, NIH 3T3 cells (e.g., ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No. CRL1721), COS cells, COS-7 cells (ATCC No. CRL1651), RAT1 cells, mouse L cells (ATCC No. CCLI.3), human embryonic kidney (HEK) cells (ATCC No. CRL1573), HLHepG2 cells, and MRC5 cells (ATCC No. CCL-171). When mammalian host cells are used, such host cells may include human cells (e.g., HeLa, 293, H9, and Jurkat cells); mouse cells (e.g., NIH3T3, L cells, and C127 cells); primate cells (e.g., Cos1, Cos7, and CV1) and hamster cells (e.g., Chinese hamster ovary (CHO) cells).

[0091] Various host-vector systems suitable for expressing polypeptides can be used according to standard procedures known in the art. See, for example, Sambrook et al., 1989, Current Protocols in Molecular Biology, Cold Spring Harbor Press, New York; Ausubel et al., 1995, Current Protocols in Molecular Biology, eds., Wiley & Sons; "Protein Expression: A Practical Approach" (1999), S.J. Higgins and B.D. James, eds., Oxford University Press; "Protein Expression in Mammalian Cells: Methods and Protocols (Methods in Molecular Biology)" (2012), James L. Hartley, ed., Humana Press; and "Production of Recombinant Proteins" (2005), Gerd Gellisen, ed., Wiley-VCH. Methods for introducing nucleic acids into host cells include, for example, transformation, electroporation, conjugation, transfection, calcium phosphate cleavage, etc. The method of transfer can be selected to result in stable expression of the polypeptide encoding the introduced nucleic acid. The polypeptide encoding nucleic acid can be provided as a heritable episomal element (e.g., a plasmid) or can be genomically integrated. A variety of suitable vectors for producing the peptide of interest are commercially available.

[0092] Suitable expression vectors include, but are not limited to, baculovirus vectors, bacteriophage vectors, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral vectors (e.g., viral vectors based on vaccinia virus, poliovirus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, HIV-based lentiviral vectors, murine leukemia virus (MVL)-based gammaretroviral vectors, etc.), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vector specific for a particular target host (e.g., E. coli, mammalian cells, insect cells, or yeast cells).

[0093] E1 and E2 polypeptides can be produced by introducing a recombinant expression vector containing a nucleotide sequence encoding E1 and / or E2 polypeptides into a suitable host cell, where the host cell produces the encoded E1 and / or E2 polypeptides. In the expression vector, a polynucleotide containing a nucleotide sequence(s) encoding E1 and / or E2 is linked to appropriate regulatory sequences to obtain the desired expression characteristics. These regulatory sequences include promoters, enhancers, terminators, operators, repressors, and inducers. Promoters can be regulatable or constitutive. Expression vectors usually have convenient restriction sites located near the promoter sequence, allowing for the insertion of a nucleic acid sequence encoding a protein of interest. A selectable marker operative in the expression host cell may also be present.

[0094] In some cases, the E1 and E2 polypeptides are encoded within a recombinant expression vector suitable for expression in eukaryotic host cells (e.g., insect cells; yeast cells; mammalian host cells such as CHO cells, HeLa cells, 293 cells, and MRC5 cells). In some cases, the recombinant expression vector comprises a nucleotide sequence encoding E1 and E2 as a single polypeptide chain; the recombinant expression vector is introduced into a eukaryotic host cell to generate a genetically modified host cell. The E1 and E2 polypeptides are initially produced as a single polypeptide chain, which is cleaved in the endoplasmic reticulum (ER) of the genetically modified host cell to produce separate E1 and E2 polypeptides. The separate E1 and E2 polypeptides may form heterodimers (e.g., non-covalently linked heterodimers) in the ER. The E1 / E2 heterodimer can be isolated from the genetically modified host cell, for example, by lysis with a non-ionic detergent. See, e.g., Frey et al. (2010) Vaccine 28:6367.

[0095] Alternatively, the E1 and E2 polypeptides are encoded on separate recombinant expression vectors; and are produced in a cell (eg, the same host cell or separate host cells) as separate polypeptides.

[0096] When full-length E1 and E2 polypeptides are expressed in eukaryotic host cells, they remain in the lumen of the endoplasmic reticulum (ER) as asialoglycoproteins. When E1 and E2 polypeptides have a C-terminal truncation such that the C-terminal transmembrane region is removed, the truncated polypeptides are secreted as glycoprotein complexes (wherein the glycosylation includes sialic acid). E1 polypeptides that have a C-terminal truncation such that the C-terminal transmembrane region is removed and the E1 polypeptide is secreted from eukaryotic cells that produce them are referred to as "soluble E1 polypeptides." Similarly, E2 polypeptides that have a C-terminal truncation such that the C-terminal transmembrane region is removed and the E2 polypeptide is secreted from eukaryotic cells that produce them are referred to as "soluble E2 polypeptides." Deletion of E2 around amino acids 662-746 or D2 around amino acids 715-746, and deletion of E1 around amino acids 330-384, result in secretion of E2 and E1 from eukaryotic host cells. When E1 and E2 are coexpressed as full-length polypeptides in the same eukaryotic host cell, E1 and E2 remain in the lumen of the ER as heterodimers.

[0097] After production in host cells, the E1 and E2 polypeptides (e.g., separately or as heterodimers) can be purified from the host cells. Methods for purifying recombinantly produced polypeptides from host cells are known in the art and include, for example, detergent lysis (e.g., with non-ionic detergents) followed by one or more of size exclusion column chromatography, high performance liquid chromatography, affinity chromatography, etc.

[0098] formulation HCV E1, E2, and E1 / E2 polypeptides can be formulated with a pharmaceutically acceptable excipient(s) to produce the immunogenic composition. A wide variety of pharmaceutically acceptable excipients are known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients are fully described in various publications, including, for example, A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy," 20th Edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) HC Cansel et al., eds., 7th Edition, Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) AH Kibbe et al., eds., 3rd Edition, American Pharmaceutical Assoc.

[0099] In some embodiments, the E1 and E2 polypeptides are formulated in an aqueous buffer. Suitable aqueous buffers include, but are not limited to, acetate buffers, succinate buffers, citrate buffers, and phosphate buffers of various strengths ranging from about 5 mM to about 100 mM. In some embodiments, the aqueous buffer contains an agent that provides an isotonic solution. Such agents include, but are not limited to, sodium chloride; and sugars, such as, for example, mannitol, dextrose, and sucrose. In some embodiments, the aqueous buffer further contains a non-ionic surfactant, such as polysorbate 20 (TWEEN® 20) or polysorbate 80 (TWEEN® 80). For example, a formulation of E1 and E2 polypeptides in an aqueous buffer may include, for example, about 0.01% to about 0.05% polysorbate 20 (TWEEN® 20) non-ionic surfactant. Optionally, the formulation may further contain a preservative. Suitable preservatives include, but are not limited to, benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, and the like. Formulations are often stored at about 4°C. Formulations may also be lyophilized, which generally include a cryoprotectant such as sucrose, trehalose, lactose, maltose, mannitol, and the like. Lyophilized formulations can be stored for extended periods, even at ambient temperatures.

[0100] The E1 and E2 polypeptides can be formulated into injectable preparations by dissolving, suspending, or emulsifying them in an aqueous or non-aqueous solvent such as vegetable oil or other similar oils, synthetic fatty acid glycerides, esters of higher fatty acids, or propylene glycol; and, if desired, together with conventional additives such as solubilizers, isotonicity adjusting agents, suspending agents, emulsifiers, stabilizers, and preservatives.

[0101] Immunogenic compositions of the disclosure may include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, etc. The compositions may also contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting agents, buffers, toxicity adjusters, etc., e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.

[0102] The concentration of HCV E1, E2, and E1 / E2 polypeptides in the formulation can vary widely (e.g., from less than about 0.1% by weight to at least about 2% by weight, to 20% to 50% by weight or more), and can be selected primarily based on fluid volume, viscosity, and patient factors, according to the particular mode of administration selected and the patient's needs.

[0103] The HCV polypeptide-containing formulations of the present disclosure may be provided in the form of solutions, suspensions, tablets, pills, capsules, powders, gels, creams, lotions, ointments, aerosols, and the like. It should be recognized that for oral administration, it may be necessary to protect the composition from digestion. This is typically accomplished either by associating the composition with an agent that confers resistance to acid and enzymatic hydrolysis, or by encapsulating the composition in a suitable resistant carrier. Means of protecting from digestion are well known in the art.

[0104] The HCV polypeptide-containing formulations of the present disclosure can also be provided to increase the serum half-life of the heterodimer after administration. For example, when formulating isolated HCV E1, E2, or E1 / E2 polypeptides for injection, the HCV polypeptides can be provided as colloids or in liposome formulations prepared by other conventional techniques to extend serum half-life. Various methods are available for preparing liposomes, such as those described in, for example, Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980); U.S. Patent Nos. 4,235,871, 4,501,728, and 4,837,028. The formulations can also be provided in controlled-release or sustained-release forms.

[0105] Adjuvants The immunogenic composition of the present disclosure may contain an adjuvant. Examples of known suitable adjuvants that can be used in humans include, but are not limited to, alum, aluminum phosphate, aluminum hydroxide, MF59 (4.3% w / v squalene, 0.5% w / v Tween 80™, 0.5% w / v Span 85), CpG-containing nucleic acids (cytosine unmethylated), QS21, MPL, 3DMPL, extracts from Aquilla, ISCOMS, LT / CT mutants, poly(D,L-lactide-co-glycolide) (PLG) microparticles, Quil A, interleukins, etc. Experimental animals can be tested using Freund's, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP19835A, referred to as MTP-PE), and RIBI, which contains three bacterial extracts in a 2% squalene / Tween 80 emulsion: monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton (MPL+TDM+CWS). The effectiveness of an adjuvant may be determined by one or more of measuring the amount of antibodies against the immunogenic antigen or its antigenic epitopes, measuring the cytotoxic T lymphocyte response against the antigen, and measuring the helper T cell response against the antigen.

[0106] Additional exemplary adjuvants for enhancing the effectiveness of the compositions include, but are not limited to, the following: (1) for example, (a) MF59™ containing 5% squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing MTP-PE) formulated into submicron particles using a microfluidizing agent (see, e.g., WO 90 / 14837); (b) microfluidized emulsions that are microfluidized to produce submicron emulsions or larger particle size emulsions; (c) SAF containing 10% squalane, 0.4% Tween 80, 5% Pluronic block polymer L121, and thr-MDP, either vortexed as in Example 1, and (d) an oil-in-water emulsion formulation such as the RIBI™ Adjuvant System (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components such as monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), e.g., MPL+CWS (Detox™), with or without other specific immunostimulators such as muramyl peptides (see below) or bacterial cell wall components; (2) QS21 or Stimulon™ (Cambridge University Press) may be used. (3) saponin adjuvants such as saponin adjuvants (e.g., saponin adjuvants such as saponin adjuvants, ... (WO99 / 44636, etc.), cytokines such as interferons (e.g., gamma interferon), macrophage colony-stimulating factor (M-CSF), and tumor necrosis factor (TNF); (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL), optionally substantially free of alum when used with pneumococcal saccharides (e.g., WO00 / 56358), e.g., GB-2220221, EP-A-0689454;(6) 3dMPL in combination with, for example, QS21 and / or oil-in-water emulsions (see, for example, EP-A-0835318, EP-A-0735898, EP-A-0761231); (7) oligonucleotides comprising CpG motifs containing at least one CG dinucleotide in which the cytosine is unmethylated (see, for example, WO96 / 02555, WO98 / 16247, WO98 / 18810, WO98 / 40100, WO98 / 55495, WO98 / 37919, and WO98 / 52581); (8) polyoxyethylene ethers or polyoxyethylene esters (see, for example, WO99 / 52549); (9) polyoxyethylene sorbitan ester surfactants in combination with octoxynol. (WO01 / 21207), or polyoxyethylene alkyl ether or ester surfactants in combination with at least one additional non-ionic surfactant such as octoxynol (WO01 / 21152); (10) saponin and immunostimulatory oligonucleotides (e.g., CpG oligonucleotides) (WO00 / 62800); (11) particles of immunostimulants and metal salts (see, e.g., WO00 / 23105); (12) saponin and oil-in-water emulsions (see, e.g., WO99 / 11241); (13) saponin (e.g., QS21) + 3dMPL + IM2 (optionally containing a sterol) (see, e.g., WO98 / 57659); (14) other substances that act as immunostimulants to enhance the efficacy of the composition. Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc. Matrix-M™ is also suitable for use;Matrix-M™ is an adjuvant containing 40 nm nanoparticles containing quillaja saponin, cholesterol, and phospholipids. Adjuvants suitable for human administration are of particular interest. In some cases, the adjuvant enhances the CD4+ T helper response to the immunogen.

[0107] In some cases, the adjuvant is MF59 with or without CpG-containing oligonucleotides. In another example, the adjuvant is alum with or without CpG-containing oligonucleotides. In another example, the adjuvant is poly(D,L-lactide-co-glycolide) with or without CpG-containing oligonucleotides. In another example, the adjuvant is MPL with or without CpG-containing oligonucleotides. In other cases, the adjuvant is Matrix-M™ with or without CpG-containing oligonucleotides.

[0108] Methods for inducing an immune response against HCV The present disclosure provides methods for inducing an immune response to at least one HCV genotype in a mammalian subject, which generally involve administering to an individual in need thereof an effective amount of the immunogenic composition.

[0109] The HCV immunogenic compositions of the present disclosure are generally administered to human subjects infected with HCV or at risk of acquiring HCV infection to prevent or at least partially halt the development of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose" or "therapeutically effective amount." "Prophylactic" use of the present immunogenic compositions generally refers to administration to individuals not infected with HCV. "Therapeutic" use of the present immunogenic compositions can refer to "prophylactic" use (administration to individuals not infected with HCV) and / or administration to individuals infected with HCV. A "therapeutically effective amount" of the immunogenic compositions of the present disclosure can be an amount effective to induce an immune response against HCV in an individual not infected with HCV, when administered in single or multiple doses to an individual infected with HCV. A "therapeutically effective amount" of the immunogenic compositions of the present disclosure can be an amount effective to enhance an immune response against HCV in an individual, when administered in single or multiple doses to an individual infected with HCV.

[0110] Amounts effective for therapeutic use will depend, for example, on the immunogenic composition, the mode of administration, the patient's weight and general health, and the judgment of the prescribing physician. Single or multiple doses of the immunogenic composition can be administered, depending on the dosage and frequency, and route of administration, as necessary and tolerated by the patient.

[0111] In some cases, an effective amount (e.g., a therapeutically effective amount) of an HCV immunogenic composition of the disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce an antibody response against HCV in the individual, e.g., antibodies against HCV (e.g., extracellular HCV) and / or HCV-infected cells.

[0112] An effective amount of the immunogenic composition of the present disclosure can be an amount effective to induce a neutralizing antibody response against various HCV genotypes (e.g., genotype 1; genotype 3; genotype 2; genotype 7; genotype 5; genotype 6, etc.) when administered once or multiple times to an individual. The neutralizing antibody response reduces HCV binding to CD81 and / or other cellular receptors, inhibiting HCV entry into cells. In some cases, an effective amount of the immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1 and genotype 3. In some cases, an effective amount of the immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1, genotype 2, and genotype 3. In some cases, an effective amount of the immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1, genotype 2, genotype 3, and genotype 7. In some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1, genotype 2, genotype 3, genotype 4, genotype 5, genotype 6, and genotype 7. For example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1a / b and genotype 3a. As another example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1a / b, genotype 2a, and genotype 3a. As another example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1a / b, genotype 2b, and genotype 3a. As another example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a neutralizing antibody response against HCV genotype 1a / b, genotype 2a, genotype 3a, genotype 4a, genotype 5a, genotype 6a, and genotype 7a.

[0113] In some cases, an effective amount (e.g., a therapeutically effective amount) of an immunogenic composition of the present disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce a cytotoxic T lymphocyte (CTL) response against HCV, e.g., can induce a CTL response against HCV-infected cells.

[0114] In some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotype 1 and genotype 3. In some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotype 1, genotype 2, and genotype 3. In some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotype 1, genotype 2, genotype 3, genotype 4, genotype 5, genotype 6, and genotype 7. For example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotype 1a / b and genotype 3a. As another example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotypes 1a / b, 2a, and 3a. As another example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotypes 1a / b, 2b, and 3a. As another example, in some cases, an effective amount of an immunogenic composition of the present disclosure is an amount effective to induce a CTL response against HCV genotypes 1a / b, 2a, 3a, 4a, 5a, 6a, and 7a.

[0115] In some cases, an effective amount (e.g., a therapeutically effective amount) of an immunogenic composition of the present disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce a helper T lymphocyte (e.g., CD4+ T cell) response against HCV in the individual.

[0116] In some cases, an effective amount (e.g., a therapeutically effective amount) of an immunogenic composition of the present disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce an antibody response (e.g., a neutralizing antibody response) and / or a CTL response and / or a helper T cell response against HCV genotype 1. In some cases, an effective amount (e.g., a therapeutically effective amount) of an immunogenic composition of the present disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce an antibody response (e.g., a neutralizing antibody response) and / or a CTL response and / or a helper T cell response against HCV genotype 3. In some cases, an effective amount (e.g., a therapeutically effective amount) of an immunogenic composition of the present disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce an antibody response (e.g., a neutralizing antibody response) and / or a CTL response and / or a helper T cell response against HCV genotype 1 and HCV genotype 3. In some cases, an effective amount (e.g., a therapeutically effective amount) of an immunogenic composition of the present disclosure is an amount that, when administered to an individual in single or multiple doses, is effective to induce an antibody response (e.g., a neutralizing antibody response) and / or a CTL response and / or a helper T cell response against HCV of any genotype.

[0117] The immunogenic compositions of the present disclosure are generally administered in an amount effective to elicit an immune response in a mammalian subject, e.g., a humoral immune response (e.g., an antibody response) and / or a CTL response. The amount effective for immunization varies and generally can range from about 1 μg to 100 μg per 70 kg patient, e.g., about 5 μg / 70 kg to about 50 μg / 70 kg. Substantial higher doses (e.g., 10 mg to 100 mg or more) are appropriate for oral, intranasal, or topical administration routes. An initial administration can be followed by booster immunizations with the same or a different HCV immunogenic composition. Optionally, the present methods of inducing an immune response include at least one booster immunization, and optionally two or more (e.g., three, four, or five) boosters, following the initial administration of an HCV immunogenic composition of the present disclosure. The interval between the first immunization and the booster immunization, or the interval between the booster immunization and the next booster immunization, can be about 1 week to about 12 weeks, for example, about 1 week to about 2 weeks, about 2 weeks to about 4 weeks, about 4 weeks to about 6 weeks, about 6 weeks to about 8 weeks, about 8 weeks to about 10 weeks, or about 10 weeks to about 12 weeks.

[0118] Generally, immunization can be achieved by administering the HCV immunogenic compositions of the present disclosure by any suitable route, including oral, nasal, nasopharyngeal, parenteral, enteral, gastric, topical, transdermal, subcutaneous, intramuscular, in tablet, solid, powder, liquid, or aerosol form, with or without excipients, locally, or systemically. Actual methods for preparing compositions for parenteral administration will be known or apparent to those skilled in the art and are described in further detail in publications such as Remington's Pharmaceutical Science, 15th Edition, Mack Publishing Company, Easton, Pa. (1980). Optionally, immunization is achieved by intramuscular injection of the HCV immunogenic compositions of the present disclosure.

[0119] In some cases, the method comprises administering to an individual in need thereof an effective amount of a composition of the present disclosure comprising E2 polypeptides and / or E1 / E2 heterodimer complexes from two different HCV genotypes described above and below in this specification, wherein the composition comprises a pharmaceutically acceptable excipient.

[0120] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 1a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0121] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising a full-length E2 polypeptide of HCV genotype 1a and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0122] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising a soluble E2 polypeptide of HCV genotype 1a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0123] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 1a, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 and / or E2N6 sites as described above; or an E1 / E2 heterodimer polypeptide complex of HCV genotype 3a, wherein the E2 polypeptide of the E1 / E2 heterodimer is wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0124] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 1a, wherein the E2 polypeptide is wild-type; or an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a, wherein the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0125] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 3a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0126] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising a full-length E2 polypeptide of HCV genotype 3a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0127] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising a soluble E2 polypeptide of HCV genotype 3a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein all polypeptides are wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 3a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0128] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 3a, wherein the E2 polypeptide comprises an asparagine modification (e.g., substitution) at the E2N1 and / or E2N6 sites as described above; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein the E2 polypeptide of the E1 / E2 heterodimer is wild-type. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0129] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 3a, wherein the E2 polypeptide is wild-type; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a, wherein the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site as described above. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes most prevalent in North America and among intravenous drug users. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 3a. Optionally, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 3a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 3a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0130] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide or E1 / E2 heterodimer polypeptide complex of HCV genotype 1a; and an E2 polypeptide or E1 / E2 heterodimer polypeptide complex of HCV genotype 2a. Optionally, all of the polypeptides are wild-type. Optionally, the genotype 1a and genotype 2a polypeptides are both E1 / E2 heterodimer polypeptides. Optionally, the genotype 1a polypeptide is an E2 polypeptide; and the genotype 2a polypeptide is an E1 / E2 heterodimer polypeptide complex. Optionally, the genotype 1a polypeptide is an E1 / E2 heterodimer polypeptide complex; and the genotype 2a polypeptide is an E2 polypeptide. Optionally, the genotype 1a and genotype 2a polypeptides are both E2 polypeptides. Optionally, the genotype 1a and genotype 2a polypeptides are both soluble E2 polypeptides. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes, such as genotypes 1a, 1b, 2a, 4, 5, and 6a. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a and 2a. In some cases, the composition is administered in an amount effective to achieve 50% or greater than 50% neutralization of HCV genotypes 1a, 1b, 2a, 4, 5, and 6a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than genotypes 1a and 2a described above, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.

[0131] In some cases, the method comprises administering to an individual in need thereof an effective amount of a composition of the present disclosure comprising E2 polypeptides and / or E1 / E2 heterodimer complexes from three different HCV genotypes described above and below in this specification, wherein the composition comprises a pharmaceutically acceptable excipient.

[0132] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 1a; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2a; and an E2 polypeptide of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0133] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 1a; an E2 polypeptide of HCV genotype 2a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0134] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; an E2 polypeptide of HCV genotype 2a; and an E2 polypeptide of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype. In some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of HCV genotype 2b.In some embodiments, the composition also includes an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0135] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2a; and an E2 polypeptide of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 2b. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0136] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E2 polypeptide of HCV genotype 1a; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 2b. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0137] Optionally, the method includes administering to an individual in need thereof an effective amount of a composition comprising an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1a; an E2 polypeptide of HCV genotype 2a; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3a. Optionally, all of the polypeptides are wild-type. In other cases, the E2 polypeptide of the E1 / E2 heterodimer comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. In other cases, the E2 polypeptide not present in the heterodimeric complex with E1 comprises an asparagine modification (e.g., substitution) at the E2N1 site and / or the E2N6 site, as described above. Optionally, at least one of the E2 polypeptides is full-length. Optionally, at least one of the E2 polypeptides is a soluble E2 polypeptide. Optionally, the composition is administered in an amount effective to neutralize HCV genotypes prevalent worldwide. In some cases, the composition is administered in an amount effective to neutralize HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to induce a CTL response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some cases, the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a. In some embodiments, the composition does not include E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of any HCV genotype other than the aforementioned genotypes 1a, 2a, and 3a, hi some embodiments, the composition also includes E1 polypeptides, E2 polypeptides, and / or E1 / E2 polypeptides of at least one additional HCV genotype.In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 2b. In some embodiments, the composition also comprises an E1 polypeptide, an E2 polypeptide, and / or an E1 / E2 polypeptide of HCV genotype 7a.

[0138] Suitable individuals for administration Individuals suitable for administration of the HCV compositions of the present disclosure include immunologically naive individuals (eg, individuals who have not been infected with HCV and / or who have not received an HCV vaccine).

[0139] Individuals suitable for administration of the HCV compositions of the present disclosure include those at greater risk of HCV infection than the general public, such as intravenous drug users; individuals who are recipients or prospective recipients of blood or blood products from another (donor) individual; individuals who are recipients or prospective recipients of non-autologous cells, tissues, or organs from another (donor) individual; healthcare workers; emergency medical personnel and non-healthcare personnel (e.g., first responders; firefighters; emergency medical team personnel; etc.).

[0140] Suitable individuals for administration of the HCV compositions of the present disclosure include those recently exposed to or infected with HCV. For example, the immunogenic compositions can be administered to individuals within about 24 hours to about 48 hours, about 48 hours to about 1 week, or about 1 week to about 4 weeks after possible or suspected exposure to or infection with HCV.

[0141] Individuals suitable for administration of the HCV compositions of the present disclosure include those diagnosed with HCV infection and those who are chronically infected. In some cases, individuals diagnosed with HCV infection are treated with an antiviral drug and the HCV immunogenic composition. Antiviral drugs suitable for treating HCV infection include, for example, ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide); interferon-alpha (IFN-α) (wherein "IFN-α" includes IFN-α2a; IFN-α2b; and IFN-α conjugated with poly(ethylene glycol) ("PEG-IFN-α"), which may be PEG-IFN-α2a or PEG-IFN-α2b); HCV NS3 protease inhibitors (e.g., boceprevir; telaprevir); and HCV NS5 protease inhibitors. In some cases, an individual diagnosed with HCV infection is treated with, for example, 1) IFN-α plus ribavirin and the HCV immunogenic composition; or 2) IFN-α plus ribavirin plus an HCV protease inhibitor (e.g., boceprevir or telaprevir) and the HCV immunogenic composition. In one non-limiting example, the HCV immunogenic composition is administered to an individual diagnosed with HCV infection once a month for six months. [Example]

[0142] The following examples are set forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use this invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations can be used, such as bp, base pairs; kb, kilobases; pl, picoliters; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acids; kb, kilobases; bp, base pairs; nt, nucleotides; im, intramuscular; ip, intraperitoneal; sc, subcutaneous, etc.

[0143] Example 1 : Genotype-specific neutralization Materials and Methods Goat immunization Goats (G714 and G757) and goats (G766 and G773) were immunized with E1E2 from HCV1 (genotype 1a) and E2 from J6 (genotype 2a), respectively. Recombinant E1E2 and soluble E2 proteins were derived from the sequences of HCV genotype 1a and 2a strains, respectively. Recombinant E1E2 proteins were purified from a Chinese hamster ovary cell line that constitutively expresses the glycoprotein; E2 protein was purified from the culture medium of 293T cells expressing the E2 glycoprotein. Goats were administered 0.5 ml of experimental vaccine consisting of 10 μg of purified protein antigen (E2E1 or E2) with either squalene-based Addavax or Freund's adjuvant. Postvaccination serum used in this data was collected 129 days after four vaccinations. Serum collected before vaccination served as a negative control.

[0144] In vitro neutralization assay Goat sera were tested for neutralizing activity after vaccination against chimeric genotype 1a H77c / JFH1 or genotype 2a J6 / JFH1 HCV (HCVcc) produced in vitro in cell culture.

[0145] 1 x 10 per well 4 Huh-7.5 cells were seeded in multiwell plates one day before infection. For infection, 300 TCID50 (50% tissue culture infectious dose) HCVcc was premixed with heat-inactivated goat serum diluted 1:50 (by volume) at 37°C for 1 hour. The premixed HCVcc / goat serum was then added to the cells. 12 hours postinfection, the antibody-virus inoculum was replaced with fresh medium. Then, 48 hours postinfection, the cells were fixed with 2% paraformaldehyde. The infection dose was quantified by flow cytometry, and the number of NS5A-positive cells, detected using a mouse monoclonal NS5A antibody (9E10), was counted. Neutralization rates were reported relative to prevaccination serum.

[0146] result The neutralizing activity of goat sera after vaccination with tissue-culture-derived chimeric genotypes 1a (H77c / JFH1) or 2a (J6 / JFH1) was tested using an in vitro neutralization assay. Goats (G714 and G757) were immunized with recombinant E1 and E2 derived from genotype 1a (G1a) sequences, whereas goats (G766 and G773) were immunized with E2 derived from genotype 2a (G2a) sequences. The G1a antigen induced strong neutralizing activity against the G1a chimeric virus H77 / JFH but was less effective against the G2a virus J6 / JFH (Figure 4). Meanwhile, the E2 antigen derived from G2a induced more effective neutralizing antibodies against the G2a virus than the G1a virus. Together, these data suggest that a universal vaccine requires an antigen cocktail to confer cross-genotypic protection.

[0147] Example 2 : Genotype-specific neutralization Materials and Methods Goat immunization Goats (G757, G714) were immunized with E1E2 from HCV-1 (genotype 1a); goats (G004, G752) were immunized with the E1 ectodomain from HCV-1 (genotype 1a); goats (G786, G799) were immunized with the E2 ectodomain from HCV-1 (genotype 1a); and goats (G766, G733) were immunized with the E2 ectodomain from J6 (genotype 2a). The E1E2 proteins, E1, and E2 ectodomains were derived from the sequences of HCV genotype 1a (H77) and HCV genotype 2a (J6) strains, respectively. Recombinant antigens were purified from a Chinese hamster ovary cell line that constitutively expresses the glycoproteins. Goats were administered 0.5 ml of experimental vaccines consisting of 10 μg of purified protein antigen (E1E2) or molar equivalents of E1 or E2 in either squalene-based AddaVax or Freund's incomplete adjuvant (IFA). Post-vaccination serum used in this data was collected 129 days after four vaccinations. Serum collected before vaccination served as a negative control. E1 and E2 extracellular domains are soluble E1 and E2 polypeptides with the C-terminal transmembrane regions removed.

[0148] In vitro neutralization assay Goat sera were tested for neutralizing activity after vaccination against chimeric genotype 1a H77c / JFH1 or genotype 2a J6 / JFH1 HCV (HCVcc) produced in vitro in cell culture.

[0149] 1 x 10 per well 4Huh-7.5 cells were seeded in multiwell plates one day before infection. For infection, 300 TCID50 (50% tissue culture infectious dose) HCVcc was premixed with heat-inactivated goat serum diluted 50:1 (by volume) at 37°C for 1 hour. The premixed HCVcc / goat serum was then added to the cells. 12 hours postinfection, the antibody-virus inoculum was replaced with fresh medium. Then, 48 hours postinfection, the cells were fixed with 2% paraformaldehyde. The infection dose was quantified by flow cytometry, and the number of NS5A-positive cells, detected using a mouse monoclonal NS5A antibody (9E10), was counted. The neutralization rate (%) was reported relative to prevaccination serum.

[0150] result Cross-neutralizing antibodies induced by the vaccine were tested. Sera diluted 1:50 were preincubated with either H77 / JFH1 (G1a) or J6 / JFH (G2a) tissue culture-derived HCV and then used to infect Huh-7.5 cells. Infection levels were monitored by NS5a staining using flow cytometry. Neutralizing activity levels were normalized to 0% for a prevaccination control set. A second set of prevaccination sera was used to demonstrate assay variability.

[0151] The results are shown in Figures 5 and 6. Figure 5 shows the ability of goat sera to neutralize HCV genotype 1a (HCV of H77 / JFH1 as the "challenge virus"), and Figure 6 shows the ability of goat sera to neutralize HCV genotype 2a (HCV of J6 / JFH as the "challenge virus").

[0152] Figure 5. Sera from goats 757, 714, 786, and 799 (immunized with HCV1(G1a)-derived antigens) showed induction of neutralizing antibodies that blocked G1a infection; however, sera from goats 766 and 773 (immunized with J6(G2a)-derived antigens) were limited in their effectiveness in blocking infection with G1a (genotype 1a) virus.

[0153] Figure 6. Sera from goats 766 and 733 (immunized with antigens derived from genotype 2a) showed greater blocking of infection with G2a (genotype 2a) virus than with G1a virus. Sera from goats immunized with antigens derived from genotype 1a (757, 714, 004, 752, 786, and 799) showed limited neutralizing activity against G2a virus.

[0154] Example 3 : Cross-neutralization Goats were immunized with the E1 / E2 heterodimer complex from HCV strain HCV1 (genotype 1a) or soluble E2 (sE2) from HCV strain J6 (genotype 2a). Postvaccination goat sera were tested for neutralizing activity against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a. The data are shown in Figures 7A and 7B. The data shown in Figure 7a indicate that immunization with E1 / E2 from HCV genotype 1a elicited neutralizing antibodies against all HCV genotypes tested except for 2a, 2b, and 3a; the data shown in Figure 7b indicate that immunization with sE2 from HCV genotype 2a elicited neutralizing antibodies against HCV genotypes 1b, 2a, 4a, and 6a.

[0155] While the present invention has been described with reference to specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, method, method step or steps to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

[0156] Sequence information SEQUENCE LISTING <110> THE GOVERNORS OF THE UNIVERSITY OF ALBERTA <120> E1E2 HCV VACCINES AND METHODS OF USE <150> US 61 / 823,712 <151> 2013-05-15 <150> US 61 / 887,229 <151> 2013-10-04 <160> 53 <170> PatentIn version 3.5 <210> 1 <211> 746 <212> PRT <213> Hepatitis C virus <400> 1 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val 225 230 235 240 Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Met Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 370 375 380 Thr His Val Thr Gly Gly Ser Ala Gly Arg Thr Thr Ala Gly Leu Val 385 390 395 400 Gly Leu Leu Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Leu Asn Thr Gly Trp Leu Ala Gly Leu Phe Tyr Gln His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Arg Leu Thr Asp 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Leu 465 470 475 480 Asp Glu Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Ser 515 520 525 Trp Gly Ala Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Met 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile Asn Tyr 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Ala Ser Trp Ala Ile Lys Trp Glu Tyr Val Val 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 2 <211> 746 <212> PRT <213> Hepatitis C virus <400> 2 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Val Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Ile Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Leu Ala Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 370 375 380 Thr Tyr Thr Thr Gly Gly Ser Val Ala Gln Ala Ala Phe Gly Leu Thr 385 390 395 400 Ser Leu Phe Arg Pro Gly Pro Lys Gln Asp Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Ser Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asn Lys Leu Gly Val Pro Thr Tyr Ser 515 520 525 Trp Gly Ser Asn Glu Thr Asp Val Leu Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Ala Gly Asn 565 570 575 Arg Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Met Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 3 <211> 746 <212> PRT <213> Hepatitis C virus <400> 3 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Phe 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asp Asn Thr Ser Arg Cys Trp Val 225 230 235 240 Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly Arg Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Ser Val Asp Ala Glu 370 375 380 Thr Tyr Thr Ser Gly Gly Ser Val Ala Arg Ala Thr Ala Gly Phe Ala 385 390 395 400 Gly Ile Phe Asn Pro Gly Ala Lys Gln Asp Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Lys Pro Leu Ala His 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Asp His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asn Lys Leu Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Ser Asn Asp Thr Asp Val Phe Ile Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gly Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Thr Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Val Thr Pro Arg Phe Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Leu Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 4 <211> 746 <212> PRT <213> Hepatitis C virus <400> 4 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Thr Ser Lys Cys Trp Val 225 230 235 240 Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Thr Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Ala Gly Asn Trp 355 360 365 Ala Lys Val Leu Leu Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 370 375 380 Thr Tyr Thr Thr Gly Gly Ser Val Ala Arg Thr Thr Arg Gly Leu Ala 385 390 395 400 Ser Leu Leu Gln Val Gly Pro Lys Gln Asp Ile Arg Leu Ile His Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Leu Ala Gly Leu Leu Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Thr Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asn Lys Leu Gly Val Pro Thr Tyr Thr 515 520 525 Trp Gly Ser Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Gln Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 5 <211> 746 <212> PRT <213> Hepatitis C virus <400> 5 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asp Asn Ala Ser Arg Cys Trp Val 225 230 235 240 Pro Val Ala Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Val Ala Leu Val Met Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Gln 370 375 380 Thr Tyr Val Thr Gly Gly Ser Ala Ala Arg Gly Ala Ser Gly Leu Ala 385 390 395 400 Asn Leu Phe Thr Pro Gly Ala Lys Gln Asp Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Lys Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Arg His Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Ser Ala Gln Thr Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asn Arg Leu Gly Val Pro Thr Tyr Ser 515 520 525 Trp Gly Thr Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 6 <211> 746 <212> PRT <213> Hepatitis C virus <400> 6 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Thr 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Glu Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Lys Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Val Ser Lys Cys Trp Val 225 230 235 240 Pro Val Ala Leu Thr Val Ala Thr Arg Asp Gly Asn Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Met Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ser Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Ser Val Asp Ala Gly 370 375 380 Thr His Val Thr Gly Gly Ser Ala Ala His Asp Val Ser Ala Leu Ala 385 390 395 400 Gly Phe Phe Arg Arg Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Val Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Leu Tyr Tyr His Arg Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr Asn Val Asp Gly Gly Gly Ser 465 470 475 480 Glu Tyr Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Glu Pro Ala Gln Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Lys Val Gly Val Pro Thr Tyr Asn 515 520 525 Trp Gly Glu Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Val Lys Val Cys Gly Ala Pro Pro Cys Ile Ile Gly Gly Ala Gly Asn 565 570 575 Lys Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Asp Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Ile Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Val Ala Ala Cys Asn Trp Thr Tyr Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 7 <211> 746 <212> PRT <213> Hepatitis C virus <400> 7 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly Thr Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Gly Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Ile Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 370 375 380 Thr His Val Thr Gly Gly Ser Ala Ala Gln Val Thr Ser Arg Val Ala 385 390 395 400 Gly Phe Phe Asn Pro Gly Pro Lys Gln Asn Val Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr His Tyr Asn Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asn Arg Leu Gly Val Pro Thr Tyr Asn 515 520 525 Trp Gly Ser Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 8 <211> 746 <212> PRT <213> Hepatitis C virus <400> 8 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Ile Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Leu Ala Pro Thr Val Ala Thr Arg Asp Gly Arg Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala His 370 375 380 Thr Arg Val Thr Gly Gly Ser Ala Ala Arg Ala Thr Ala Arg Leu Thr 385 390 395 400 Thr Leu Phe Ser Pro Gly Ala Lys Gln Asp Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Ile Pro Ala Lys Thr Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Phe Asn 515 520 525 Trp Gly Asp Asn Asp Thr Asp Val Leu Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Tyr 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Ile Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Val Glu Ala 740 745 <210> 9 <211> 746 <212> PRT <213> Hepatitis C virus <400> 9 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Arg Leu Pro Ala Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Ile Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Gly 370 375 380 Thr His Val Thr Gly Gly Ser Ala Ala Lys Asp Thr Ser Gly Phe Thr 385 390 395 400 Ser Leu Phe Arg Ile Gly Ala Arg Gln Asn Ile Gln Leu Ile Asn Ser 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Leu Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Ser Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Lys Ser Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Cys Asn Glu Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Ala Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 10 <211> 746 <212> PRT <213> Hepatitis C virus <400> 10 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Arg Leu Pro Ala Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Ile Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Gly 370 375 380 Thr His Val Thr Gly Gly Ser Ala Ala Lys Asp Thr Ser Gly Phe Thr 385 390 395 400 Ser Leu Phe Arg Ile Gly Ala Arg Gln Asn Ile Gln Leu Ile Asn Ser 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Leu Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Ser Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Lys Ser Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Cys Asn Glu Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Ala Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 11 <211> 746 <212> PRT <213> Hepatitis C virus <400> 11 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Arg Leu Pro Ala Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Ile Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Gly 370 375 380 Thr His Val Thr Gly Gly Ser Ala Ala Lys Asp Thr Ser Gly Phe Thr 385 390 395 400 Ser Leu Phe Arg Ile Gly Ala Arg Gln Asn Ile Gln Leu Ile Asn Ser 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Leu Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Ser Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Lys Ser Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Cys Asn Glu Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Ala Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 12 <211> 746 <212> PRT <213> Hepatitis C virus <400> 12 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Ser Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 370 375 380 Thr His Thr Thr Gly Gly Ser Ala Ala Tyr Ala Thr Ser Gly Phe Val 385 390 395 400 Gly Leu Phe Arg Gln Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Val Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Lys Pro Leu Ala Asn 450 455 460 Phe Asp Gln Gly Trp Gly Ser Ile Ser Tyr Thr Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr Phe Asn 515 520 525 Trp Gly Glu Asn Glu Ser Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Ser Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Asn Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Val Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Leu Asn Tyr 610 615 620 Ser Leu Phe Lys Val Arg Met Tyr Val Gly Gly Ile Glu His Arg Leu 625 630 635 640 Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Thr Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Val Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Ile Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 13 <211> 746 <212> PRT <213> Hepatitis C virus <400> 13 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 180 185 190 Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Lys Cys Trp Val 225 230 235 240 Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly Arg Leu Pro Thr Thr 245 250 255 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg His His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Val Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Thr 370 375 380 Thr His Thr Thr Gly Gly Ala Val Ala His Asn Thr Arg Met Phe Thr 385 390 395 400 Ser Ile Phe Ser Leu Gly Pro Arg Gln Glu Ile Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Ala Ser 420 425 430 Leu Glu Thr Gly Trp Ile Ala Gly Leu Leu Tyr Ala Asn Arg Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Lys Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly Pro 465 470 475 480 Glu His Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Gln Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Thr Pro Thr Tyr Asp 515 520 525 Trp Gly Ser Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Pro Ala Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Tyr 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Ser Asn 565 570 575 Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Ala Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Ser Ile Val Ser Trp Ala Val Lys Trp Glu Tyr Val Ile 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ser Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Ala Glu Ala 740 745 <210> 14 <211> 746 <212> PRT <213> Hepatitis C virus <400> 14 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ala Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 245 250 255 Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Leu Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ala 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Gly 370 375 380 Thr Tyr Val Thr Gly Gly Thr Met Ala Lys Asn Thr Leu Gly Ile Thr 385 390 395 400 Ser Leu Phe Ser Pro Gly Ser Ser Gln Lys Ile Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Asn Thr Gly Phe Leu Ala Ala Leu Phe Tyr Val His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Ser Pro Ile Asp Ala 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Thr Tyr Asn Glu Ser His Ser Ser 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Ala Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Ser 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ile Gly Asn 565 570 575 Lys Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Val Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Val Val Ser Phe Ala Ile Lys Trp Glu Tyr Val Leu 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 15 <211> 746 <212> PRT <213> Hepatitis C virus <400> 15 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Val Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 245 250 255 Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Ile Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Glu 370 375 380 Thr Arg Val Thr Gly Gly Gln Ile Ala Arg Asn Ala Tyr Ser Leu Thr 385 390 395 400 Thr Leu Phe Ser Ser Gly Ser Ala Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Asn Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr His Lys Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro Ile Asp Lys 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr Tyr Ala Glu Gln Gly Gly Gln 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Lys Pro Cys Gly Ile 485 490 495 Val Ser Ala Ser Lys Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Ser 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Gly Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Ala Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ala Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Glu Asp 645 650 655 Arg Asp Arg Leu Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Val Val Ser Phe Ala Ile Lys Trp Asp Tyr Ile Val 705 710 715 720 Ile Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 16 <211> 747 <212> PRT <213> Hepatitis C virus <400> 16 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Ile Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Leu Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Gly Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala His 180 185 190 Glu Val Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Phe Glu Ala Ala Asp Leu Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Thr Ile Pro Thr Thr 245 250 255 Thr Ile Arg His His Val Asp Leu Leu Val Gly Ala Ala Ala Leu Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Ala Thr Leu Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ala Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Ile Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Ala Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly His 370 375 380 Thr Leu Thr Thr Gly Gly His Ala Ala Arg Leu Thr Ser Gly Phe Ala 385 390 395 400 Gly Leu Phe Thr Pro Gly Pro Ser Gln Arg Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Gln Thr Gly Phe Leu Ala Ala Leu Phe Tyr Ala His Arg Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Ser Ile Asp Lys 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr Tyr Ala Glu Pro Thr Lys Asp 465 470 475 480 Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Gln Gln Cys Gly 485 490 495 Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Asn Pro Thr Tyr 515 520 525 Ser Trp Gly Glu Asn Asp Thr Asp Val Leu Leu Leu Asn Asn Thr Arg 530 535 540 Pro Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Thr Lys Thr Cys Gly Ala Pro Pro Cys Asn Ile Gly Gly Val Gly 565 570 575 Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu 580 585 590 Ala Thr Tyr Ser Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys 595 600 605 Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn 610 615 620 Phe Ser Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg 625 630 635 640 Leu Asn Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Asp 645 650 655 Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu 660 665 670 Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr 675 680 685 Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr 690 695 700 Gly Ile Gly Ser Ala Val Val Ser Phe Ala Ile Lys Trp Glu Tyr Val 705 710 715 720 Val Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu 725 730 735 Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 17 <211> 746 <212> PRT <213> Hepatitis C virus <400> 17 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg His Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Val Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Gln Asp Gly Asn Thr Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Val Thr 245 250 255 Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Pro Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Gln Thr Val Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Met Ile Val Leu Leu Leu Phe Ala Gly Val Asp Gly Thr 370 375 380 Thr His Thr Thr Gly Gly Ala Ala Ala Arg Ala Thr Gln Gly Phe Thr 385 390 395 400 Ser Phe Phe Ser Leu Gly Pro Ser Gln Lys Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Gln Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr Tyr Arg Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Ile Asp Lys 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr Tyr Ala Glu Pro Asp Ser Ser 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Thr 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn 565 570 575 Thr Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Ala Val Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asn Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Val Ile Pro Phe Ala Ile Lys Trp Glu Tyr Val Leu 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 18 <211> 746 <212> PRT <213> Hepatitis C virus <400> 18 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ile Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Lys Asn Ile Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ile Ser Val Pro Thr Ala 245 250 255 Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Trp His Glu Thr Val Gln Asp Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Ile Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Ala Asp Gly Thr 370 375 380 Thr His Val Thr Gly Gly Val Gln Ala His Gly Ala Tyr Gly Leu Ala 385 390 395 400 Ser Leu Phe Asn Val Gly Pro His Gln Lys Ile Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Thr 420 425 430 Leu Gln Thr Gly Phe Leu Ala Ala Leu Phe Tyr Lys His Arg Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Ile Asp Lys 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Thr Tyr Ala Glu Pro Asp Arg Leu 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Leu Glu Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Ser 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Tyr 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Ile Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Arg Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Val Val Ser Phe Ala Ile Lys Trp Glu Tyr Val Leu 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 19 <211> 746 <212> PRT <213> Hepatitis C virus <400> 19 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Val Ile Met His Ala Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 245 250 255 Thr Leu Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Ile Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Met Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly His 370 375 380 Thr Arg Val Thr Gly Gly Val Gln Gly His Val Thr Ser Thr Leu Thr 385 390 395 400 Ser Leu Phe Arg Pro Gly Ala Ser Gln Lys Ile Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Lys Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr His Lys Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Ser Ile Asp Lys 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr Tyr Ala Gln Pro Asp Asn Ser 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Gln Cys Gly Ile 485 490 495 Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Asp Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro His Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Arg Gly Val Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Asp Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ala Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Leu Pro Cys Ser Tyr Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Ile Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Val Val Ser Ile Ala Ile Lys Trp Glu Tyr Val Val 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 20 <211> 746 <212> PRT <213> Hepatitis C virus <400> 20 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asp Glu Gly Met Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ile Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Lys Asn Thr Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ile Ser Val Pro Thr Thr 245 250 255 Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Ala Asp Gly Thr 370 375 380 Thr His Val Thr Gly Gly Val Gln Ala His Gly Ala Tyr Gly Leu Ala 385 390 395 400 Ser Leu Phe Asn Val Gly Pro His Gln Lys Ile Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Thr 420 425 430 Leu Gln Thr Gly Phe Leu Ala Ala Leu Phe Tyr Lys His Arg Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Ile Asp Lys 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Thr Tyr Ala Glu Pro Asp Arg Leu 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Leu Glu Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Ser 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Asn Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Val Phe Lys Val Arg Met Tyr Val Gly Gly Ile Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Arg Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Val Val Ser Phe Ala Ile Lys Trp Glu Tyr Ile Leu 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 21 <211> 746 <212> PRT <213> Hepatitis C virus <400> 21 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asp Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ser Ser Val Pro Thr Thr 245 250 255 Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Ile Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Val Gln Asp Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Asn 370 375 380 Thr Arg Val Ser Gly Gly Glu Ala Ala Lys Asn Thr Met Gly Phe Ala 385 390 395 400 Ser Leu Phe Val Ser Gly Pro Ser Gln Lys Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asp Asp Ser 420 425 430 Leu His Thr Gly Phe Leu Ala Ala Leu Phe Tyr Ala His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Ser Gly Arg Met Ala Ser Cys Arg Pro Ile Asp Glu 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Thr His Gly Val Pro Asp Asn Leu 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Ala Pro Thr Tyr Ser 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Val Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Val Val Val Ser Val Val Ile Arg Trp Glu Tyr Val Val 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 22 <211> 746 <212> PRT <213> Hepatitis C virus <400> 22 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Leu His Ala Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 245 250 255 Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Leu Leu Val Ser 275 280 285 Gln Ile Phe Thr Phe Ser Pro Arg Arg His Glu Thr Met Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Gly 370 375 380 Thr Tyr Val Thr Gly Gly Glu Ala Gly Arg Arg Thr Ser Gly Phe Ala 385 390 395 400 Ser Ile Phe Thr Pro Gly Ala Ser Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu His Thr Gly Phe Ile Ala Ala Leu Phe Tyr His His Lys Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Ile Gly Glu 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Ser Tyr Thr Glu Pro Pro Ser Ser 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Asp Asn Asp Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Ile 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Thr Lys Ile Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Met Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Ile Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Ala Val Ser Phe Ala Ile Arg Trp Glu Tyr Val Leu 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 23 <211> 746 <212> PRT <213> Hepatitis C virus <400> 23 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Leu His Ala Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 245 250 255 Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Leu Leu Val Ser 275 280 285 Gln Ile Phe Thr Phe Ser Pro Arg Arg His Glu Thr Met Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Gly 370 375 380 Thr Tyr Val Thr Gly Gly Glu Ala Gly Arg Arg Thr Ser Gly Phe Ala 385 390 395 400 Ser Ile Phe Thr Pro Gly Ala Ser Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu His Thr Gly Phe Ile Ala Ala Leu Phe Tyr His His Lys Phe Asn 435 440 445 Ala Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Ile Gly Glu 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Ser Tyr Thr Glu Pro Pro Ser Ser 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Leu Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Asp Asn Asp Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Ile 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Thr Lys Ile Arg Met Tyr Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Met Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Ile Gln Tyr Leu Tyr Gly 690 695 700 Ile Gly Ser Ala Ala Val Ser Phe Ala Ile Arg Trp Glu Tyr Val Leu 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 24 <211> 746 <212> PRT <213> Hepatitis C virus <400> 24 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Thr Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 180 185 190 Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Met Ile Met His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Asp Asn Phe Thr Arg Cys Trp Val 225 230 235 240 Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Gly Ser Val Pro Thr Thr 245 250 255 Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 275 280 285 Gln Leu Phe Thr Phe Ser Pro Arg Trp His Glu Thr Val Gln Glu Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Ile Val Thr Leu Leu Phe Ala Gly Val Asp Gly Asn 370 375 380 Thr His Thr Ile Gly Gly Lys Gln Ala Gln Ala Thr Gly Gly Phe Val 385 390 395 400 Ala Trp Leu Ala Arg Gly Pro Ser Gln Glu Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Lys Thr Gly Phe Ile Ala Ala Leu Phe Tyr Ala His Arg Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Arg Pro Ile Asp Lys 450 455 460 Phe Ala Gln Gly Trp Gly Pro Ile Thr Tyr Ala Lys Pro Asp Ser Leu 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Gln Pro Cys Gly Ile 485 490 495 Val Pro Ala Ser Glu Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Val Pro Thr Tyr Arg 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro 530 535 540 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ala Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Gly Pro Pro Cys Lys Ile Gly Gly Leu Gly Asn 565 570 575 Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Ile 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe 610 615 620 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Ile Glu His Arg Leu 625 630 635 640 Ser Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp 645 650 655 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp 660 665 670 Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Thr Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Val Gly Ser Val Leu Val Ser Phe Ala Ile Lys Trp Glu Tyr Ile Leu 705 710 715 720 Leu Phe Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ala Gln Ala Glu Ala 740 745 <210> 25 <211> 746 <212> PRT <213> Hepatitis C virus <400> 25 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asn Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Cys Leu Leu Pro Arg Arg Gly Pro Arg Val Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Arg Gly Pro Ser Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Val 180 185 190 Glu Val Arg Asn Ser Ser Gly Ile Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ala Ser Val Val Tyr Glu Thr Asp Ser Leu Ile Ile His Leu Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val 225 230 235 240 Ser Leu Ser Pro Thr Val Ala Ala Lys Asp Pro Gly Val Pro Val Asn 245 250 255 Glu Ile Arg Arg His Val Asp Leu Ile Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Ile Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Leu Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Gly Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Val Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Pro Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Thr 370 375 380 Thr Gln Val Thr Gly Gly Thr Ala Gly Arg Asn Ala Tyr Arg Leu Ala 385 390 395 400 Ser Leu Phe Ser Thr Gly Pro Ser Gln Asn Ile Gln Leu Ile Asn Ser 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu His Thr Gly Trp Val Ala Ala Leu Phe Tyr Ser His Lys Phe Asn 435 440 445 Ser Ser Gly Arg Pro Glu Arg Met Ala Ser Cys Arg Pro Leu Thr Ala 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr Tyr Gly Gly Lys Ala Ser Asn 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Lys Glu Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Lys Tyr Gly Val Pro Thr Tyr Thr 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Ser Arg Pro 530 535 540 Pro Ile Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Ala Pro Ala Cys Asn Val Gly Gly Ser Glu Thr 565 570 575 Asn Thr Leu Ser Cys Pro Thr Asp Cys Phe Arg Arg His Pro Asp Ala 580 585 590 Thr Tyr Ala Lys Cys Gly Ser Gly Pro Trp Leu Asn Pro Arg Cys Met 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Ile Phe Lys Ile Arg Met Phe Val Gly Gly Ile Glu His Arg Leu 625 630 635 640 Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ala Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Leu Ser Ser Val Val Thr Ser Trp Ala Ile Arg Trp Glu Tyr Val Val 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp 725 730 735 Met Met Leo Leo Ile Ser Gln Val Glu Ala 740 745 <210> 26 <211> 746 <212> PRT <213> Hepatitis C virus <400> 26 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Tyr 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Val 180 185 190 Gly Val Arg Asn Ser Ser Gly Val Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ala Ser Val Val Tyr Glu Thr Asp Ser Leu Ile Ile His Leu Pro 210 215 220 Gly Cys Val Pro Cys Val Arg Glu Gly Asn Gly Ser Arg Cys Trp Val 225 230 235 240 Ser Leu Ser Pro Thr Val Ala Ala Lys Asp Pro Gly Val Pro Val Asn 245 250 255 Glu Ile Arg Arg His Val Asp Leu Ile Ala Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly His Leu Cys Gly Ser Ile Phe Leu Val Gly 275 280 285 Gln Leu Phe Thr Leu Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 355 360 365 Thr Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Thr 370 375 380 Thr Ile Val Ser Gly Gly Ser Ala Gly Arg Ser Thr Ala Gly Leu Val 385 390 395 400 Gly Leu Phe Ser Pro Gly Ala Arg Gln Asn Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Thr 420 425 430 Leu Gln Thr Gly Trp Val Ala Gly Leu Phe Tyr Thr Asn Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Ala Asp 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Thr Asn Gly Ser Gly Pro 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly Ile 485 490 495 Val Pro Ala Glu Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Asn 515 520 525 Trp Gly Glu Asn Glu Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro 530 535 540 Arg Leu Gly Asn Trp Phe Gly Gly Thr Trp Met Asn Ser Thr Gly Phe 545 550 555 560 Thr Lys Val Cys Gly Ala Pro Pro Cys Ala Ile Gly Gly Val Gly Asn 565 570 575 Asn Thr Leu Tyr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu 595 600 605 Ile His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile Asn Tyr 610 615 620 Thr Ile Phe Lys Ile Arg Met Phe Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ala Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Leu Ser Ser Ala Val Thr Ser Trp Val Ile Lys Trp Glu Tyr Val Val 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Val Glu Ala 740 745 <210> 27 <211> 746 <212> PRT <213> Hepatitis C virus <400> 27 Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Val Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Ser Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 130 135 140 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 145 150 155 160 Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Val 180 185 190 Gly Val Arg Asn Ser Ser Gly Val Tyr His Val Thr Asn Asp Cys Pro 195 200 205 Asn Ala Ser Val Val Tyr Glu Thr Glu Asn Leu Ile Met His Leu Pro 210 215 220 Gly Cys Val Pro Tyr Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val 225 230 235 240 Ser Leu Ser Pro Thr Val Ala Ala Arg Asp Ser Arg Val Pro Val Ser 245 250 255 Glu Val Arg Arg Arg Val Asp Ser Ile Val Gly Ala Ala Ala Phe Cys 260 265 270 Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Ile Phe Leu Val Gly 275 280 285 Gln Ile Phe Thr Phe Ser Pro Arg His His Trp Thr Thr Gln Asp Cys 290 295 300 Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Thr Gly Ala Leu Val Val Ala Gln 325 330 335 Leu Leu Arg Ile Pro Gln Ala Ile Val Asp Met Ile Ala Gly Ala His 340 345 350 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 355 360 365 Ala Lys Val Val Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 370 375 380 Thr Arg Val Thr Gly Gly Ala Ala Gly His Thr Ala Phe Gly Phe Ala 385 390 395 400 Ser Phe Leu Ala Pro Gly Ala Lys Gln Lys Ile Gln Leu Ile Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Leu Asp Thr Gly Trp Leu Ala Gly Leu Leu Tyr Tyr His Lys Phe Asn 435 440 445 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Gln Pro Leu Thr Ala 450 455 460 Phe Asp Gln Gly Trp Gly Pro Ile Thr His Glu Gly Asn Ala Ser Asp 465 470 475 480 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Leu Arg Pro Cys Gly Ile 485 490 495 Val Pro Ala Lys Lys Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser 500 505 510 Pro Val Val Val Gly Thr Thr Asp Arg Ala Gly Val Pro Thr Tyr Arg 515 520 525 Trp Gly Ala Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Ser Arg Pro 530 535 540 Pro Met Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Ser Gly Phe 545 550 555 560 Thr Lys Thr Cys Gly Ala Pro Ala Cys Asn Ile Gly Gly Ser Gly Asn 565 570 575 Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe Arg Lys His Pro Asp Ala 580 585 590 Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu 595 600 605 Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Tyr 610 615 620 Thr Ile Phe Lys Ile Arg Met Phe Val Gly Gly Val Glu His Arg Leu 625 630 635 640 Asp Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp Asp 645 650 655 Arg Asp Arg Ala Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln Trp 660 665 670 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685 Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700 Leu Ser Ser Ala Val Thr Ser Trp Val Ile Lys Trp Glu Tyr Val Val 705 710 715 720 Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp 725 730 735 Met Met Leu Leu Ile Ser Gln Val Glu Ala 740 745 <210> 28 <211> 752 <212> PRT <213> Hepatitis C virus <400> 28 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu 180 185 190 Glu Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr 225 230 235 240 Pro Val Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala 245 250 255 Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly 275 280 285 Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Leu Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Ala Val Gly Met Val Val Ala His 325 330 335 Val Leu Arg Leu Pro Gln Thr Leu Phe Asp Ile Met Ala Gly Ala His 340 345 350 Trp Gly Ile Leu Ala Gly Leu Ala Tyr Tyr Ser Met Gln Gly Asn Trp 355 360 365 Ala Lys Val Ala Ile Ile Met Val Met Phe Ser Gly Val Asp Ala His 370 375 380 Thr Tyr Thr Thr Gly Gly Thr Ala Ser Arg His Thr Gln Ala Phe Ala 385 390 395 400 Gly Leu Phe Asp Ile Gly Pro Gln Gln Lys Leu Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Ile Asn Thr Gly Phe Ile Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Thr Gly Cys Pro Gln Arg Leu Ser Ser Cys Lys Pro Ile Thr Phe 450 455 460 Phe Arg Gln Gly Trp Gly Pro Leu Thr Asp Ala Asn Ile Thr Gly Pro 465 470 475 480 Ser Asp Asp Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Asp 485 490 495 Ile Val Pro Ala Ser Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Ala Arg Gly Val Pro Thr Tyr 515 520 525 Thr Trp Gly Glu Asn Glu Lys Asp Val Phe Leu Leu Lys Ser Gln Arg 530 535 540 Pro Pro Ser Gly Arg Trp Phe Gly Cys Ser Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Leu Lys Thr Cys Gly Ala Pro Pro Cys Asn Ile Tyr Gly Gly Glu 565 570 575 Gly Asn Pro His Asn Glu Ser Asp Leu Phe Cys Pro Thr Asp Cys Phe 580 585 590 Arg Lys His Pro Glu Thr Thr Tyr Ser Arg Cys Gly Ala Gly Pro Trp 595 600 605 Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 610 615 620 Pro Cys Thr Val Asp Phe Arg Leu Phe Lys Val Arg Met Phe Val Gly 625 630 635 640 Gly Phe Glu His Arg Phe Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu 645 650 655 Arg Cys Asp Ile Glu Asp Arg Asp Arg Ser Glu Gln His Pro Leu Leu 660 665 670 His Ser Thr Thr Glu Leu Ala Ile Leu Pro Cys Ser Phe Thr Pro Met 675 680 685 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 690 695 700 Val Gln Tyr Leu Tyr Gly Val Gly Ser Gly Met Val Gly Trp Ala Leu 705 710 715 720 Lys Trp Glu Phe Val Ile Leu Val Phe Leu Leu Leu Ala Asp Ala Arg 725 730 735 Val Cys Val Ala Leu Trp Leu Met Leu Met Ile Ser Gln Thr Glu Ala 740 745 750 <210> 29 <211> 752 <212> PRT <213> Hepatitis C virus <400> 29 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Gln Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu 180 185 190 Glu Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr 225 230 235 240 Pro Val Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala 245 250 255 Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly 275 280 285 Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Leu Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Ala Val Gly Met Val Val Ser His 325 330 335 Val Leu Arg Leu Pro Gln Thr Leu Phe Asp Ile Ile Ala Gly Ala His 340 345 350 Trp Gly Ile Leu Ala Gly Leu Ala Tyr Tyr Ser Met Gln Gly Asn Trp 355 360 365 Ala Lys Val Ala Val Ile Met Val Met Phe Ser Gly Val Asp Ala Glu 370 375 380 Thr Tyr Ile Thr Gly Gly Ser Ala Ala His Gly Val Ser Thr Leu Thr 385 390 395 400 Ser Leu Phe Ser Ser Gly Pro Gln Gln Lys Leu Gln Leu Val Lys Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Ile Asn Thr Gly Phe Ile Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Thr Gly Cys Pro Gln Arg Leu Ser Ser Cys Lys Pro Ile Thr Phe 450 455 460 Phe Arg Gln Gly Trp Gly Ser Leu Thr Asp Ala Asn Val Thr Gly Ala 465 470 475 480 Ser Ala Asp Lys Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Asp 485 490 495 Val Val Pro Ala Leu Asn Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Arg Lys Gly Val Pro Thr Tyr 515 520 525 Asn Trp Gly Glu Asn Glu Ser Asp Val Phe Leu Leu Glu Ser Leu Arg 530 535 540 Pro Pro Ser Gly Arg Trp Phe Gly Cys Ala Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Leu Lys Thr Cys Gly Ala Pro Pro Cys Asn Ile Tyr Gly Gly Gly 565 570 575 Gly Asn Pro Asn Asn Glu Ser His Leu Phe Cys Pro Thr Asp Cys Phe 580 585 590 Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly Ala Gly Pro Trp 595 600 605 Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 610 615 620 Pro Cys Thr Val Asn Phe Thr Leu Phe Lys Val Arg Met Phe Val Gly 625 630 635 640 Gly Phe Glu His Arg Phe Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu 645 650 655 Arg Cys Asn Ile Glu Asp Arg Asp Arg Ser Glu Gln His Pro Leu Leu 660 665 670 His Ser Thr Thr Glu Leu Ala Ile Leu Pro Cys Ser Phe Thr Pro Met 675 680 685 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 690 695 700 Val Gln Tyr Leu Tyr Gly Val Gly Ser Gly Met Val Gly Trp Ala Leu 705 710 715 720 Lys Trp Glu Phe Val Ile Leu Ile Phe Leu Leu Leu Ala Asp Ala Arg 725 730 735 Val Cys Val Ala Leu Trp Leu Met Leu Met Ile Ser Gln Ala Glu Ala 740 745 750 <210> 30 <211> 752 <212> PRT <213> Hepatitis C virus <400> 30 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Cys Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Arg Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Gln Ser Gly Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu 180 185 190 Glu Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Gln Asn Asp Asn Ile Ser Thr Cys Trp Thr 225 230 235 240 Pro Val Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala 245 250 255 Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly 275 280 285 Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Leu Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Phe Pro Ala Leu Gly Met Ala Val Ala His 325 330 335 Val Leu Arg Val Pro Gln Thr Leu Phe Asp Ile Ile Ala Gly Ala His 340 345 350 Trp Gly Ile Leu Ala Gly Leu Ala Tyr Tyr Ser Met Gln Gly Asn Trp 355 360 365 Ala Lys Val Ala Ile Ile Met Val Met Phe Ser Gly Val Asp Ala Val 370 375 380 Thr Tyr Thr Thr Gly Gly Ser Ala Ala His Ala Thr Arg Gly Leu Thr 385 390 395 400 Ser Leu Phe Ser Val Gly Ala Gln Gln Lys Leu Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser 420 425 430 Ile Asn Thr Gly Phe Ile Ala Gly Leu Phe Tyr Tyr His Arg Phe Asn 435 440 445 Ser Thr Gly Cys Pro Gln Arg Leu Ser Ser Cys Lys Pro Ile Thr Phe 450 455 460 Phe Lys Gln Gly Trp Gly Pro Leu Thr Asp Ala Asn Ile Ser Gly Pro 465 470 475 480 Ser Asp Asp Lys Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Lys 485 490 495 Val Val Pro Ala Ser Gly Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Ala Lys Gly Val Pro Thr Tyr 515 520 525 Thr Trp Gly Ala Asn Asp Thr Asp Val Phe Leu Leu Glu Ser Leu Arg 530 535 540 Pro Pro Gly Gly Arg Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Val Lys Thr Cys Gly Ala Ser Pro Cys Asp Ile Tyr Gly Gly Gly 565 570 575 Gly Asn Ser Gly Asn Glu Ser Asp Leu Phe Cys Pro Thr Asp Cys Phe 580 585 590 Arg Lys His Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ala Gly Pro Trp 595 600 605 Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 610 615 620 Pro Cys Thr Val Asn Phe Thr Leu Phe Lys Val Arg Met Phe Val Gly 625 630 635 640 Gly Phe Glu His Arg Phe Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu 645 650 655 Arg Cys Asp Ile Glu Asp Arg Asp Arg Ser Glu Gln His Pro Leu Leu 660 665 670 His Ser Thr Thr Glu Leu Ala Ile Leu Pro Cys Ser Phe Thr Pro Met 675 680 685 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 690 695 700 Val Gln Tyr Leu Tyr Gly Val Gly Ser Gly Met Val Gly Trp Ala Leu 705 710 715 720 Lys Trp Glu Phe Val Ile Leu Ile Phe Leu Leu Leu Ala Asp Arg Arg 725 730 735 Val Cys Val Ala Leu Trp Leu Met Leu Met Ile Thr Gln Ala Glu Ala 740 745 750 <210> 31 <211> 752 <212> PRT <213> Hepatitis C virus <400> 31 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Val 1 5 10 15 Cys Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu 180 185 190 Glu Trp Arg Asn Val Ser Gly Leu Tyr Ile Leu Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Ile Pro Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr 225 230 235 240 Ala Leu Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala 245 250 255 Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly 275 280 285 Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Leu Thr Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Ala Val Gly Met Val Val Ala His 325 330 335 Val Leu Arg Leu Pro Gln Thr Leu Phe Asp Ile Ile Ala Gly Ala His 340 345 350 Trp Gly Ile Leu Ala Gly Leu Ala Tyr Tyr Ser Met Gln Gly Asn Trp 355 360 365 Ala Lys Val Ile Ile Ile Met Val Met Phe Ser Gly Val Asp Ala Thr 370 375 380 Thr His Val Thr Gly Gly Thr Ala Gly Leu Thr Ala Phe Arg Leu Thr 385 390 395 400 Gly Leu Phe Thr Val Gly Pro Gln Gln Lys Leu Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 420 425 430 Leu Asn Thr Gly Phe Ile Ala Gly Leu Phe Arg Phe His Lys Phe Asn 435 440 445 Ser Thr Gly Cys Pro Glu Met Leu Ser Ser Cys Lys Pro Ile Thr Ser 450 455 460 Phe Lys Gln Gly Trp Gly Pro Leu Thr Asp Ala Asn Ile Thr Ile Pro 465 470 475 480 Ser Asp Asp Arg Pro Tyr Cys Trp His Tyr Pro Pro Arg Ser Cys Glu 485 490 495 Val Val Pro Ala Leu Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Ala Lys Gly Val Pro Thr Tyr 515 520 525 Thr Trp Gly Glu Asn Glu Thr Asp Val Phe Leu Leu Lys Ser Leu Arg 530 535 540 Pro Pro Gly Gly Arg Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Val Gln Thr Cys Gly Ala Pro Pro Cys Asn Ile Tyr Gly Gly Gly 565 570 575 Gly Asp Leu Lys Asn Glu Ser Asp Leu Phe Cys Pro Thr Asp Cys Phe 580 585 590 Arg Lys His Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ala Gly Pro Trp 595 600 605 Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 610 615 620 Pro Cys Thr Val Asn Phe Thr Leu Phe Lys Val Arg Met Phe Val Gly 625 630 635 640 Gly Phe Glu His Arg Phe Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu 645 650 655 Arg Cys Asp Ile Glu Asp Arg Asp Arg Ser Glu Leu His Pro Leu Leu 660 665 670 His Ser Thr Thr Glu Leu Ala Ile Leu Pro Cys Ser Phe Thr Pro Met 675 680 685 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 690 695 700 Val Gln Tyr Leu Tyr Gly Val Gly Ser Gly Met Val Gly Trp Ala Val 705 710 715 720 Lys Trp Glu Phe Val Ile Leu Val Phe Leu Leu Leu Ala Asp Ala Arg 725 730 735 Val Cys Val Ala Leu Trp Leu Met Leu Met Ile Ser Gln Ala Glu Ala 740 745 750 <210> 32 <211> 752 <212> PRT <213> Hepatitis C virus <400> 32 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu 180 185 190 Gln Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr 225 230 235 240 Pro Val Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala 245 250 255 Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly 275 280 285 Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Leu Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Ala Ala Gly Met Val Val Ala His 325 330 335 Ile Leu Arg Leu Pro Gln Thr Leu Phe Asp Ile Ile Ala Gly Ala His 340 345 350 Trp Gly Ile Leu Ala Gly Leu Ala Tyr Tyr Ser Met Gln Gly Asn Trp 355 360 365 Ala Lys Val Ala Ile Ile Met Val Met Phe Ser Gly Val Asp Ala Thr 370 375 380 Thr Tyr Thr Ser Gly Gly Ser Val Ala Gln Gln Ala Arg Gly Leu Ala 385 390 395 400 Asp Leu Phe Ser Val Gly Ala Lys Gln Asn Leu Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asp Asp Ser 420 425 430 Ile Asn Thr Gly Phe Ile Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Thr Gly Cys Pro Gln Arg Leu Ser Asp Cys Lys Pro Ile Thr Phe 450 455 460 Phe Lys Gln Gly Trp Gly Pro Leu Thr Asp Ala Asn Ile Thr Gly Pro 465 470 475 480 Ser Asp Asp Lys Pro Tyr Cys Trp His Tyr Ala Pro Arg Arg Cys Gly 485 490 495 Val Val Pro Ala Ser Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Ala Lys Gly Val Pro Thr Tyr 515 520 525 Thr Trp Gly Ala Asn Glu Thr Asp Val Phe Leu Leu Glu Ser Leu Arg 530 535 540 Pro Pro Ser Gly Arg Trp Phe Gly Cys Ala Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Leu Lys Thr Cys Gly Ala Pro Pro Cys Asn Ile Tyr Gly Gly Gly 565 570 575 Gly Asn Pro His Asn Glu Ser Asp Leu Phe Cys Pro Thr Asp Cys Phe 580 585 590 Arg Lys His Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ala Gly Pro Trp 595 600 605 Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 610 615 620 Pro Cys Thr Val Asn Phe Thr Leu Phe Lys Met Arg Thr Phe Val Gly 625 630 635 640 Gly Phe Glu His Arg Phe Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu 645 650 655 Arg Cys Asp Ile Glu Asp Arg Asp Arg Ser Glu Gln His Pro Leu Leu 660 665 670 His Ser Thr Thr Glu Leu Ala Ile Leu Pro Cys Ser Phe Thr Pro Met 675 680 685 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 690 695 700 Val Gln Tyr Leu Tyr Gly Val Gly Ser Gly Met Val Gly Trp Ala Leu 705 710 715 720 Lys Trp Glu Phe Val Ile Leu Val Phe Leu Leu Leu Ala Asp Ala Arg 725 730 735 Val Cys Val Ala Leu Trp Leu Met Leu Met Ile Ser Gln Ala Glu Ala 740 745 750 <210> 33 <211> 752 <212> PRT <213> Hepatitis C virus <400> 33 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu 180 185 190 Gln Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Val Pro Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr 225 230 235 240 Pro Val Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala 245 250 255 Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys 260 265 270 Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly 275 280 285 Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys 290 295 300 Asn Cys Ser Leu Tyr Pro Gly His Leu Ser Gly His Arg Met Ala Trp 305 310 315 320 Asp Met Met Met Asn Trp Ser Pro Ala Ala Gly Met Val Val Ala His 325 330 335 Ile Leu Arg Leu Pro Gln Thr Leu Phe Asp Ile Ile Ala Gly Ala His 340 345 350 Trp Gly Ile Leu Ala Gly Leu Ala Tyr Tyr Ser Met Gln Gly Asn Trp 355 360 365 Ala Lys Val Ala Ile Ile Met Val Met Phe Ser Gly Val Asp Ala Thr 370 375 380 Thr Tyr Thr Ser Gly Gly Ser Val Ala Gln Gln Ala Arg Gly Leu Ala 385 390 395 400 Asp Leu Phe Ser Val Gly Ala Lys Gln Asn Leu Gln Leu Val Asn Thr 405 410 415 Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asp Asp Ser 420 425 430 Ile Asn Thr Gly Phe Ile Ala Gly Leu Phe Tyr Tyr His Lys Phe Asn 435 440 445 Ser Thr Gly Cys Pro Gln Arg Leu Ser Asp Cys Lys Pro Ile Thr Phe 450 455 460 Phe Lys Gln Gly Trp Gly Pro Leu Thr Asp Ala Asn Ile Thr Gly Pro 465 470 475 480 Ser Asp Asp Lys Pro Tyr Cys Trp His Tyr Ala Pro Arg Arg Cys Gly 485 490 495 Val Val Pro Ala Ser Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 500 505 510 Ser Pro Val Val Val Gly Thr Thr Asp Ala Lys Gly Val Pro Thr Tyr 515 520 525 Thr Trp Gly Ala Asn Glu Thr Asp Val Phe Leu Leu Glu Ser Leu Arg 530 535 540 Pro Pro Ser Gly Arg Trp Phe Gly Cys Ala Trp Met Asn Ser Thr Gly 545 550 555 560 Phe Leu Lys Thr Cys Gly Ala Pro Pro Cys Asn Ile Tyr Gly Gly Gly 565 570 575 Gly Asn Pro His Asn Glu Ser Asp Leu Phe Cys Pro Thr Asp Cys Phe 580 585 590 Arg Lys His Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ala Gly Pro Trp 595 600 605 Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 610 615 620 Pro Cys Thr Val Asn Phe Thr Leu Phe Lys Met Arg Thr Phe Val Gly 625 630 635 640 Gly Phe Glu His Arg Phe Thr Ala Ala Cys Asn Trp Thr Arg Gly Glu 645 650 655 Arg Cys Asp Ile Glu Asp Arg Asp Arg Ser Glu Gln His Pro Leu Leu 660 665 670 His Ser Thr Thr Glu Leu Ala Ile Leu Pro Cys Ser Phe Thr Pro Met 675 680 685 Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp 690 695 700 Val Gln Tyr Leu Tyr Gly Val Gly Ser Gly Met Val Gly Trp Ala Leu 705 710 715 720 Lys Trp Glu Phe Val Ile Leu Val Phe Leu Leu Leu Ala Asp Ala Arg 725 730 735 Val Cys Val Ala Leu Trp Leu Met Leu Met Ile Ser Gln Ala Glu Ala 740 745 750 <210> 34 <211> 752 <212> PRT <213> Hepatitis C virus <400> 34 Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 1 5 10 15 Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 20 25 30 Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Cys Ala 35 40 45 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 50 55 60 Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 65 70 75 80 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 85 90 95 Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 100 105 110 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 115 120 125 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 130 135 140 Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp 145 150 155 160 Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 165 170 175 Phe Leu Leu Ala Leu Phe Ser Cys Leu Val His Pro Ala Ala Ser Leu 180 185 190 Glu Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Pro 195 200 205 Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro 210 215 220 Gly Cys Ile Pro ...

Claims

1. (a) a Hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a first HCV genotype; (b) an HCV E1 polypeptide, E2 polypeptide, or E1E2 polypeptide from a second HCV genotype; (c) a pharma- ceutically acceptable excipient; Including, Provided that the immunogenic composition comprises at least one E1 polypeptide and at least one E2 polypeptide.

2. 2. The composition of claim 1, wherein the first HCV genotype is genotype 1; and the second HCV genotype is genotype 2.

3. 2. The composition of claim 1, wherein the first HCV genotype is genotype 1; and the second HCV genotype is genotype 3.

4. (i) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E1 / E2 polypeptide of HCV genotype 3; (ii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E2 polypeptide of HCV genotype 3; (iii) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (iv) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (v) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; and the E2 polypeptide of HCV genotype 2; (vi) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (vii) an E1 polypeptide of HCV genotype 1; and an E2 polypeptide of HCV genotype 3; (viii) the E1 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) an E2 polypeptide of HCV genotype 1; and an E1 polypeptide of HCV genotype 3; (x) the E2 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xi) an E1 polypeptide of HCV genotype 1; and an E2 polypeptide of HCV genotype 2; (xii) the E1 polypeptide of HCV genotype 1; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; (xiii) an E2 polypeptide of HCV genotype 1; and an E1 polypeptide of HCV genotype 2; or (xiv) E2 polypeptide of HCV genotype 1; and E1 / E2 heterodimeric polypeptide complex of HCV genotype 2. The composition of claim 1 comprising:

5. 5. The composition of claim 4, further comprising an HCV E1, E2, or E1 / E2 polypeptide of a third HCV genotype.

6. 2. The composition of claim 1, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type and the HCV E2 polypeptide from the second HCV genotype is wild-type.

7. 2. The composition of claim 1, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type and the HCV E2 polypeptide from the second HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site.

8. 2. The composition of claim 1, wherein the HCV E2 polypeptide from the first HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site, and the HCV E2 polypeptide from the second HCV genotype is wild-type.

9. The composition of claim 1 , wherein the pharma- ceutically acceptable excipient comprises an adjuvant.

10. 2. The composition of claim 1, wherein the adjuvant is MF59, alum, poly(DL-lactide-co-glycolide), or a CpG oligonucleotide.

11. (a) a Hepatitis C virus (HCV) E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a first HCV genotype; (b) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a second HCV genotype; (c) an HCV E1 polypeptide, E2 polypeptide, or E1 / E2 polypeptide from a third HCV genotype; (d) a pharma- ceutically acceptable excipient; Including, Provided that the immunogenic composition comprises at least one E1 polypeptide and at least one E2 polypeptide.

12. 12. The immunogenic composition of claim 11, wherein the first HCV genotype is genotype 1, the second HCV genotype is genotype 2, and the third HCV genotype is genotype 3.

13. (i) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ii) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and the E2 polypeptide of HCV genotype 3; (iii) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (iv) the E2 polypeptide of HCV genotype 1; the E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and the E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (v) the E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; the E2 polypeptide of HCV genotype 2; and the E2 polypeptide of HCV genotype 3; (vi) an E2 polypeptide of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E2 polypeptide of HCV genotype 3; (vii) an E2 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (viii) an E1 polypeptide of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (ix) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (x) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E1 / E2 heterodimeric polypeptide complex of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; (xi) an E1 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xii) an E2 polypeptide of HCV genotype 1; an E1 polypeptide of HCV genotype 2; and an E1 / E2 heterodimeric polypeptide complex of HCV genotype 3; (xiii) an E1 / E2 heterodimeric polypeptide complex of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; (xiv) an E1 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E2 polypeptide of HCV genotype 3; (xv) an E2 polypeptide of HCV genotype 1; an E1 polypeptide of HCV genotype 2; and an E2 polypeptide of HCV genotype 3; (xvi) an E2 polypeptide of HCV genotype 1; an E2 polypeptide of HCV genotype 2; and an E1 polypeptide of HCV genotype 3; or (xvii) E1 polypeptides of HCV genotype 1; E1 / E2 heterodimeric polypeptide complexes of HCV genotype 2; and E2 polypeptides of HCV genotype 3. The immunogenic composition of claim 11 .

14. 12. The composition of claim 11, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype is wild-type.

15. 12. The composition of claim 11, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site.

16. 12. The composition of claim 11, wherein the HCV E2 polypeptide from the first HCV genotype is wild-type, the HCV E2 polypeptide from the second HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site, and the HCV E2 polypeptide from the third HCV genotype is wild-type.

17. 12. The composition of claim 11, wherein the HCV E2 polypeptide from the first HCV genotype comprises an asparagine amino acid substitution at the E2N1 site and / or the E2N6 site, the HCV E2 polypeptide from the second HCV genotype is wild-type, and the HCV E2 polypeptide from the third HCV genotype is wild-type.

18. The composition of claim 11 , wherein the pharma- ceutically acceptable excipient comprises an adjuvant.

19. The composition of claim 11, wherein the adjuvant is MF59, alum, poly(DL-lactide-co-glycolide), or a CpG oligonucleotide.

20. 1. A method for inducing an immune response in an individual, comprising: The method comprises administering to the individual an effective amount of a composition according to any one of claims 1 to 19.

21. (a) a hepatitis C virus (HCV) E2 polypeptide of HCV genotype 1a; (b) an HCV E1 / E2 heterodimeric polypeptide of HCV genotype 3a; (c) a pharma- ceutically acceptable excipient; A composition comprising:

22. The composition of claim 21 , wherein all of the polypeptides are wild-type.

23. The composition of claim 21 , wherein the E2 polypeptide is full-length.

24. 22. The composition of claim 21, wherein the E2 polypeptide is a soluble E2 polypeptide.

25. (a) a Hepatitis C virus (HCV) E2 polypeptide or an HCV E1 / E2 heterodimer polypeptide of HCV genotype 3a; (b) an HCV E2 polypeptide or an HCV E1 / E2 heterodimer polypeptide of HCV genotype 1a; (c) a pharma- ceutically acceptable excipient; A composition comprising:

26. The composition of claim 25 , wherein all of the polypeptides are wild-type.

27. The composition of claim 25 , wherein the E2 polypeptide is full-length.

28. 26. The composition of claim 25, wherein the E2 polypeptide is a soluble E2 polypeptide.

29. 1. A method for inducing an immune response in an individual, comprising: administering to said individual an effective amount of a composition according to any one of claims 21 to 28, The method wherein the composition is administered in an amount effective to induce neutralizing antibodies against at least HCV genotypes 1a and 3a.

30. 1. A method for inducing an immune response in an individual, comprising: administering to said individual an effective amount of a composition according to any one of claims 21 to 28, The method wherein the composition is administered in an amount effective to induce a cytotoxic T lymphocyte response against at least HCV genotypes 1a and 3a.

31. 1. A method for inducing an immune response in an individual, comprising: administering to said individual an effective amount of a composition according to any one of claims 21 to 28, The method, wherein the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 3a.

32. (a) a Hepatitis C virus (HCV) E2 polypeptide or an HCV E1 / E2 heterodimer polypeptide of HCV genotype 2a; (b) an HCV E2 polypeptide or an HCV E1 / E2 heterodimer polypeptide of HCV genotype 1a; (c) a pharma- ceutically acceptable excipient; A composition comprising:

33. The composition of claim 32 , wherein all of the polypeptides are wild-type.

34. The composition of claim 32, wherein the E2 polypeptide is full-length.

35. 33. The composition of claim 32, wherein the E2 polypeptide is a soluble E2 polypeptide.

36. 1. A method for inducing an immune response in an individual, comprising: administering to said individual an effective amount of a composition according to any one of claims 32 to 35; The method wherein the composition is administered in an amount effective to induce neutralizing antibodies against at least HCV genotypes 1a and 2a.

37. 1. A method for inducing an immune response in an individual, comprising: administering to said individual an effective amount of a composition according to any one of claims 32 to 35; The method wherein the composition is administered in an amount effective to induce a cytotoxic T lymphocyte response against at least HCV genotypes 1a and 2a.

38. 1. A method for inducing an immune response in an individual, comprising: administering to said individual an effective amount of a composition according to any one of claims 32 to 35; The method, wherein the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a and 2a.

39. (a) a hepatitis C virus (HCV) E2 or HCV E1 / E2 heterodimeric polypeptide of HCV genotype 1a; (b) an HCV E2 polypeptide or an HCV E1 / E2 heterodimer polypeptide of HCV genotype 2a; (c) an E2 polypeptide of HCV genotype 3a or an HCV E1 / E2 heterodimer polypeptide; (d) a pharma- ceutically acceptable excipient; A composition comprising:

40. 40. The composition of claim 39, wherein all of the polypeptides are wild-type.

41. 40. The composition of claim 39, wherein at least one of the E2 polypeptides is full-length.

42. 40. The composition of claim 39, wherein at least one of the E2 polypeptides is a soluble E2 polypeptide.

43. The composition according to any one of claims 39 to 42, comprising an E1 / E2 polypeptide of HCV genotype 7a.

44. The composition of any one of claims 39 to 42, comprising an E2 polypeptide of HCV genotype 7a.

45. 1. A method for inducing an immune response in an individual, comprising: administering to the individual an effective amount of a composition according to any one of claims 39 to 44; The method wherein the composition is administered in an amount effective to induce neutralizing antibodies against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a.

46. 1. A method for inducing an immune response in an individual, comprising: administering to the individual an effective amount of a composition according to any one of claims 39 to 44; The method, wherein the composition is administered in an amount effective to induce a cytotoxic T lymphocyte response against HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a.

47. 1. A method for inducing an immune response in an individual, comprising: administering to the individual an effective amount of a composition according to any one of claims 39 to 44; The method, wherein the composition is administered in an amount effective to achieve 50% or greater neutralization of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a, and 7a.